



HOKKAIDO UNIVERSITY

Title	Prenatal organochlorine pesticide exposure and the disruption of steroids and reproductive hormones in cord blood : The Hokkaido study
Author(s)	Araki, Atsuko; Miyashita, Chihiro; Mitsui, Takahiko et al.
Citation	Environment international, 110, 1-13 https://doi.org/10.1016/j.envint.2017.10.006
Issue Date	2018-01
Doc URL	https://hdl.handle.net/2115/76437
Rights	© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Rights(URL)	https://creativecommons.org/licenses/by-nc-nd/4.0/
Type	journal article
File Information	ENVINT_2017_824_(final).pdf



Prenatal organochlorine pesticide exposure and the disruption of steroids and reproductive hormones in cord blood: The Hokkaido Study

Atsuko Araki^a, Chihiro Miyashita^a, Takahiko Mitsui^{b,c}, Houman Goudarzi^{a,d}, Futoshi Mizutani^e, Youichi Chisaki^e, Sachiko Itoh^a, Seiko Sasaki^f, Kazutoshi Cho^g, Kimihiko Moriya^h, Nobuo Shinohara^h, Katsuya Nonomura^{h,i}, and Reiko Kishi^a

^aCenter for Environmental and Health Sciences, Hokkaido University, Kita 12, Nishi 7, Sapporo, Hokkaido, Japan

^bDepartment of Urology, Hokkaido University Hospital, Kita 15, Nishi 7, Sapporo, Hokkaido, Japan

^cYamanashi University, 1110, Shimogato, Chuo, Yamanashi, Japan

^dDepartment of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Sapporo, Hokkaido, Japan

^eInstitute of Environmental Ecology, IDEA Consultants, Inc., 1334-5 Riemon, Yaizu, Shizuoka, Japan

^fDepartment of Public Health, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Sapporo, Hokkaido, Japan

^gMaternity and Perinatal Care Center, Hokkaido University Hospital, Kita 15, Nishi 7, Sapporo, Hokkaido, Japan

^hDepartment of Renal and Genitourinary Surgery, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Sapporo, Hokkaido, Japan

ⁱKushiro Rosai Hospital, 13-23, Nakazono-cho, Kushiro, Hokkaido, Japan

Word count: 4882

25 *Number tables: 6*

26 *Number of figures: 1*

27

28 *Correspondence*

29 Reiko Kishi, MD, PhD, MPH

30 Hokkaido University

31 Center for Environmental and Health Sciences,

32 Kita 12 Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-0812, Japan

33 Phone: +81-11-706-4746

34 Fax: +81-11-706-4725

35 E-mail: rkishi@med.hokudai.ac.jp

36

37

38 Conflicts of interest: none

39 .

119
120
121
122
123 41 **Abstract**
124

125 42 Certain organochlorine pesticides (OCPs) are designated as persistent organic pollutants
126
127 43 and are regulated in many countries. The effects of OCPs on pediatric endocrinology are
128
129 44 a concern; however, only limited data exist from human studies on maternal OCP
130
131 45 exposure and its effects on infants' hormone levels. This study was conducted as part of
132
133 46 the Hokkaido Study Sapporo Cohort, a prospective birth cohort study in Japan.
134
135 47 Participants included 514 women who enrolled at 23–35 weeks of gestation between
136
137 48 2002 and 2005; maternal blood samples were collected in late pregnancy, and 29 OCPs
138
139 49 were measured. Reproductive and steroid hormone levels in cord blood were also
140
141 50 determined. Characteristics of mothers and their infants were obtained from self-
142
143 51 administered questionnaires and medical records. Ultimately, 232 samples with both
144
145 52 OCP and hormone data were analyzed. Fifteen of 29 investigated OCPs were detected
146
147 53 in over 80% of the samples, with *p,p'*-dichlorodiphenyldichloroethylene showing the
148
149 54 highest concentration (median value: 619 pg/g-wet). The association between OCPs and
150
151 55 sex hormone levels varied by sex. Linear regression models after sex stratification
152
153 56 showed that chlordanes, cis-hexachlorobenzene, heptachlor epoxide, Mirex, and
154
155 57 toxaphenes in maternal blood were inversely associated with testosterone, cortisol,
156
157 58 cortisone, sex hormone-binding globin, prolactin, and androstenedione-
158
159 59 dehydroepiandrosterone (DHEA) and testosterone-androstenediones ratios among boys.
160
161 60 Furthermore, these OCPs were positively correlated with DHEA, follicle stimulating
162
163 61 hormone (FSH), and adrenal androgen-glucocorticoid and FSH-inhibin B ratios among
164
165 62 boys. In categorical quartile models, testosterone and DHEA were inversely and
166
167 63 positively associated with OCPs, respectively. Estradiol-testosterone and adrenal
168
169 64 androgen-glucocorticoid ratios tended to increase with increasing OCP concentrations
170
171
172
173
174
175
176
177

in the higher quartile, while the testosterone-androstenedione ratio tended to decrease.

Sex hormone-binding globulin and prolactin showed an inverse association with OCPs.

Among girls, the linear regression model showed that only *p,p'*-dichlorodiphenyltrichloroethane was inversely associated with the level of DHEA and the adrenal androgen-glucocorticoid ratio, but was positively associated with cortisone levels. However, no associations were observed using the quartile categorical model.

These results suggest that prenatal exposure to OCPs disrupt reproductive hormones of fetuses in utero among boys, even at relatively low levels.

Key Words: Organochlorine pesticides; reproductive hormones; steroidal hormones; prenatal exposure; cord blood; birth cohort

Abbreviations:

CI, confidence interval

CYP11A1, cytochrome P450 family 11 subfamily A member 1

CYP17A1, cytochrome P450 family 17 subfamily A member 1

CYP19A1, cytochrome P450 family 19 subfamily A member 1

DDD, dichlorodiphenyldichloroethane

DDE, dichlorodiphenyldichloroethylene

DDT, dichlorodiphenyltrichloroethane

HCB, hexachlorobenzene

HCE, heptachlor epoxide

HCH, hexachlorocyclohexane

HSD17B1, hydroxysteroid 17-beta dehydrogenase 1

- 237
238
239
240
241 89 HSD3B1, hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1
242
243 90 IRMA, immunoradiometric assay
244
245 91 DHEA, dehydroepiandrosterone
246
247 92 EIA, enzyme immunoassay
248
249 93 ELISA, enzyme-linked immunosorbent assay
250
251 94 FSH, follicle stimulation hormone
252
253 95 INSL3, insulin-like factor 3
254
255 96 LC-MSMS, liquid chromatography-tandem mass spectrometry
256
257 97 LH, luteinizing hormone
258
259 98 LSM, least square mean
260
261 99 OCP, organochlorine pesticides
262
263 100 SHBG, sex hormone-binding globulin
264
265 101 StAR, steroidogenic acute regulatory protein
266
267 102
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295

1. Introduction

Organochlorine pesticides (OCPs) are chlorinated hydrocarbons used extensively in the 1940s for agriculture and pesticide control, and are now designated as persistent organic pollutants by the Stockholm Convention (<http://chm.pops.int>). Although the Stockholm Convention has issued an exemption for the production and public health use of dichlorodiphenyltrichloroethane (DDT) to control vector-borne diseases, most OCPs were banned in the United States, Europe, and many other countries in the early 1970s (WHO, 2012). The use of OCPs has been eliminated or restricted in Japan since the 1970's (Kanazawa et al. 2012). Although most OCPs have been prohibited for over 30 years, they are still detected in the environment and in human populations. According to Japanese monitoring data, the levels of DDT and its metabolites in water and sediment have decreased since 1990 and have consistently remained low since 2000; however, they are still detectable (Ministry of Environment, Japan 2006). Heptachlor epoxide (HCE), hexachlorocyclohexane (HCH), Mirex, Parlar-26, and Parlar-50 are also above detectable levels in water and sediments, even though the latter three have never been used in Japan (Ministry of Environment, Japan 2006).

The endocrine disrupting properties of OCPs are considered a health concern. In previous cross-sectional studies among adults, heptachlor and *o,p'*-DDT concentrations were associated with lower testosterone levels in men (Freire et al. 2014). In women, hexachlorobenzene (HCB), *p,p'*-DDT, *p,p'*-dichlorodiphenyldichloroethane (DDD), endosulfan, aldrin, and Mirex showed inverse associations with luteinizing hormone (LH) and follicle stimulation hormone (FSH) while showing positive associations with prolactin (Freire et al. 2014).

Maternal exposure to OCPs may affect fetal hormone levels. Sex steroid hormones including testosterone, progesterone, and estradiol exert their functions predominantly in the gonads, and dehydroepiandrosterone (DHEA) and androstenedione are activated to form androgens and estrogens that have important roles in sex differentiation and maturation (Labrie et al. 2001). Cortisol and cortisone are synthesized within the adrenal cortex, are involved in a wide range of physiological processes, and are essential for regulating and/or modulating homeostasis in metabolism, growth, neurodevelopment, and the immune system (Braun et al. 2013; Reynolds 2010). LH and FSH play critical roles in the development and regulation of numerous body functions via the hypothalamic-pituitary-gonadal (HPG) axis (Kuiri-Hänninen et al. 2014). Inhibin B and insulin-like factor-3 (INSL3) are major products secreted by the Leydig and Sertoli cells, respectively, and the establishment of sufficient numbers of these cells is critical for the production of sperms in adulthood (Ivell et al. 2013; Orth and Boehm 1990). In response to gonadotropins, testosterone (via LH signaling) and inhibin B together act to regulate the secretion of FSH; these constitute the major negative feedback signals that maintain the physiological function of the HPG axis (Carlson, 2009). However, only limited data exist regarding human studies on prenatal exposure to OCPs and their effects on steroids and reproductive hormone levels in offspring. There is only one study in France that found that prenatal α -endosulfan and HCE increase estradiol and sex hormone-binding globulin (SHBG), whereas these same agents reduce testosterone levels at birth (Warembourg et al. 2016).

We have previously reported that 21 of 29 tested OCPs were detected in maternal blood acquired between 2002 and 2005 in Japan (Kanazawa et al. 2012). The impact of relatively low levels of OCP exposure on hormones at birth has still not been

well-investigated in epidemiological studies. In particular, the effects of OCPs other than DDTs are rarely investigated. Thus, we hypothesized that prenatal exposure to even relatively low levels of these agents may alter hormone levels in infants. To that end, the aim of this study was to examine the associations between prenatal OCP exposure and cord blood steroid and reproductive hormone levels.

2. Methods

2.1 Participants

This investigation was based on the Sapporo Cohort of the Hokkaido Study on Environment and Children's Health. Details of this study, including the population, data collection, sampling of the biological specimens, and contents of the administered questionnaire, were described previously (Kishi et al. 2017; Kishi et al. 2013; Kishi et al. 2011). Briefly, Japanese pregnant women who lived in Sapporo City or surrounding areas were recruited at 23–35 weeks of gestation between July 2002 and October 2005 at an obstetrics and gynecology hospital in Sapporo, Hokkaido, Japan. Among the 1796 eligible women approached, 25% were excluded because they were enrolled in the Japanese Cord Blood Bank or planned to deliver at another hospital. Ultimately, 514 pregnant women (28.6% of those approached) were enrolled in this study.

2.2 OCP measurement

Maternal blood samples were obtained at the time of patients' hospital examinations following recruitment (n=296). If a blood sample could not be obtained during pregnancy because of maternal anemia, a sample was collected during post-partum hospitalization within a week after delivery (n=130). All samples were stored at –80°C

until analysis. OCPs in whole blood were measured by gas chromatography/high-resolution mass spectrometry and gas chromatography/negative-ion chemical-ionization mass spectrometry at IDEA Consultants, Inc. (Shizuoka, Japan) The 29 OCPs evaluated in this study were 5 chlordanes (*cis*-chlordanes, *trans*-chlordanes, *cis*-nonachlor, *trans*-nonachlor, and oxychlordanes), 6 DDTs (*o,p'*-DDT, *p,p'*-DDT, *o,p'*-DDE, *p,p'*-DDE, *o,p'*-DDD, and *p,p'*-DDD), 3 'drins' (aldrin, dieldrin, and endrin), 3 heptachlors (heptachlors, *cis*-HCE, and *trans*-HCE), HCB, 4 HCH isomers (α -HCH, β -HCH, γ -HCH, and δ -HCH), Mirex, and 6 toxaphenes (Parlar-26, Parlar-41, Parlar-40, Parlar-44, Parlar-50, and Parlar-62). Details of the measurement methods have been described previously (Kanazawa et al. 2012).

2.3 Measurement of steroids and reproductive hormones

The methods used to measure steroids and reproductive hormones were described previously (Araki et al. 2017; Araki et al. 2014; Goudarzi et al. 2016). Briefly, the concentrations of 7 steroid hormones including progesterone, estradiol, testosterone, DHEA, androstenedione, cortisol, and cortisone in cord blood were measured using liquid chromatography-tandem mass spectrometry (LC-MSMS) (Yamashita et al. 2007a; Yamashita et al. 2007b). An immunoradiometric assay (IRMA) was used to measure the concentrations of LH, FSH, and prolactin (Spac-S LH Kit, Spac-S FSH Kit, and Spac-Prolactin Kit, respectively, TFB, Inc., Tokyo Japan). SHBG was also measured using IRMA-Count SHBG (Siemens, Berlin, Germany). Concentrations of inhibin B were measured by using an enzyme-linked immunosorbent assay (ELISA) (Inhibin B Gen ELISA, Beckman Coulter, Inc., CA, USA), while INSL3 was measured by using an enzyme immunoassay (EIA) (INSL3/RLF [human] EIA kit, Phoenix

Pharmaceutical., Inc., CA, USA). All hormone measurements were conducted at Aska Pharma Medical Co., Ltd (Kanagawa, Japan).

2.4 Questionnaires and medical records

The participants completed a self-administered questionnaire that extracted information on maternal age, education level, household income, maternal smoking and alcohol consumption during the first trimester, and medical history. Information at the time of delivery, including pre-pregnancy body mass index, pregnancy complications, gestational age, infant sex, parity, congenital anomalies such as hypospadias and cryptorchidism, and infant size was obtained from medical records (Kishi et al. 2013; Kishi et al. 2011).

2.5 Statistical analyses

Of the 514 participants, 10 were excluded from the study owing to miscarriage, stillbirth, relocation, or voluntary withdrawal prior to delivery. Among 426 maternal blood samples, 379 were of sufficient quantity for OCP analysis, while hormone measurements were obtained from 295 infant cord blood samples. Ultimately, 232 matched maternal serum and cord blood samples (for OCP and hormone levels measurements, respectively) were included in the statistical analysis.

Associations between maternal OCP concentrations and infant steroid hormone levels were examined for each OCP separately via linear regression analysis. In each model, the OCP was the independent variable while the hormone was the dependent variable. Initially, linear regression models for both sexes combined were constructed with the interaction terms of sex $\times$ OCP levels added in each model; this revealed

significant differences between the sexes. Next, the models were applied following stratification by sex. OCP levels and the concentrations of steroid hormones were converted to a $\log_{10}$ scale because they were not normally distributed. Two-sided P -values <0.05 were considered statistically significant. Selected OCPs with P -values <0.1 in linear regression models were then categorized into concentration quartiles to examine dose-response relationships. The interquartile range for each OCP concentration and the least squares means (LSM) of log-transformed hormone levels were calculated and back-transformed. To calculate a P -value for the trend, linear contrast coefficients of -3 , -1 , $+1$, and $+3$ were assigned to the first, second, third, and fourth quartiles, respectively (Goudarzi et al., 2016; Itoh et al., 2016). P -values for trend <0.05 were considered statistically significant. The OCP levels in the first quartile were also compared to those in the second, third, and fourth quartiles using the Dunnett-Hsu method; P -values were adjusted using Bonferroni's correction ($P<0.0167$). When below their detection limits, the half values of these detection limits were used for both OCPs and hormones.

In addition to single hormone levels, we also examined the product-to-substrate ratios of hormones that are adjacent in the metabolic pathway to determine their enzyme activity indices (Hicks et al. 2014). For example, the estradiol-testosterone ratio represents the index of the cytochrome P450 family 19 subfamily A member 1 (CYP19A1), better known as aromatase. The androstenedione-DHEA ratio represents the hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 (HSD3B1) index; the testosterone-androstenedione ratio represents the hydroxysteroid 17-beta dehydrogenase 1 (HSD17B1) index; and the cortisone-cortisol ratio represents the HSD3B1 index. Increasing and decreasing ratios suggest the up- and

downregulation of enzyme activity, respectively. Additionally, the adrenal androgen (the sum of DHEA and androstenedione)-glucocorticoid (sum of cortisol and cortisone) ratio was examined to determine the balance shift of adrenal androgen (C19-steroids) and glucocorticoid (C21-steroids) (Goudarzi et al. 2016). Similarly, testosterone-LH and FSH-inhibin B ratios were examined as indices of gonadal function. The inclusion of covariates was examined based on biological considerations, and included maternal age (continuous), parity (primipara or multipara), and gestational age (continuous). All statistical analyses were performed using the Japanese version of IBM SPSS Statistics 19 (IBM Analytics, NC, USA) and the Japanese version of JMP Pro 12 (SAS Institute Inc., NC, USA).

2.6 Ethical approval

This study was approved by the Institutional Ethical Board for Epidemiological Studies at Hokkaido University Graduate School of Medicine and Hokkaido University Center for Environmental and Health Sciences, in accordance with the principles of the Declaration of Helsinki. All participants provided written informed consent.

3. Results

Table 1 shows the characteristics of the participants included in this study as well as those of the original cohort. Compared to the original cohort, the mean birth weight and gestational age were slightly larger among the participants; the vaginal delivery rate among participants was 99.1%. One infant with cryptorchidism was included in the study.

269 The concentrations of OCP in maternal blood samples are shown in Table 2.

270 There were 15 OCPs (3 chlordanes [*cis*-nonachlor, *trans*-nonachlor, and oxychlordanes],

271 5 DDTs [*o,p'*-DDT, *p,p'*-DDT, *o,p'*-DDE, *p,p'*-DDE, *p,p'*-DDD], dieldrin, *cis*-HCE,

272 HCB, β -HCH, Mirex, and 2 toxaphenes [Parlar-26 and Parlar-50]) that were above 80%

273 of their detection limits; these OCPs were subjected to further analysis. The median

274 concentration of *p,p'*-DDE was the highest at 619.26 pg/g-wet, followed by β -HCH at

275 154.31 pg/g-wet, and HCH at 103.99 pg/g-wet. The distributions of OCPs in the

276 original cohort are shown in Supplemental Table S1; *trans*-chlordanes, *cis*-nonachlor,

277 and *trans*-nonachlor levels of participants in this study were slightly higher compared

278 with the levels in those who were excluded (Mann-Whitney U test, $P=0.06$, 0.039, and

279 0.040, respectively; data not shown). Associations between OCP levels and maternal

280 and child characteristics are shown in Supplemental Table S1. The levels of most OCPs

281 increased with the ages of the mothers. OCP concentrations were not significantly

282 associated with infant characteristics such as sex, birth weight, or gestational age.

283 The steroid and reproductive hormone levels in infants are shown in Table 3.

284 Testosterone and DHEA levels were significantly higher and lower in boys than in girls,

285 respectively. The detection rate of LH, FSH, and inhibin B was below 30% in girls,

286 among whom only 16 samples were analyzed for INSL3. Therefore, no further tests of

287 LH, FSH, inhibin B, and INSL3 were conducted for girls. The distribution of all

288 measured hormone levels are shown in Supplemental Table S3; there were no

289 differences between subjects included and excluded from the study.

290 The associations between OCPs and steroid and reproductive hormone levels for

291 both sexes combined were examined (Supplemental Table S4). Sex-specific OCP

292 interactions ($P<0.05$) between one or more hormones and *cis*-nonachlor, *trans*-

293 nonachlor, *p,p'*-DDE, *o,p'*-DDT, dieldrin, and Mirex were observed, suggesting that the
294 effects of OCPs differ according to sex.

295 Adjusted regression coefficients (β) and 95% confidence intervals (CIs) for the
296 association between a 10-fold increase of OCP and log₁₀-transformed hormone levels as
297 determined by a linear regression model in boys and girls are shown in Tables 4 and 5,
298 respectively. Among infant boys, Mirex was inversely associated with testosterone, and
299 *p,p'*-DDE showed a positive association with the estradiol-testosterone ratio.

300 Oxychlordan, *cis*-nonachlor, *trans*-nonachlor, dieldrin, *cis*-HCE, HCB, Mirex, Parlar-
301 26, and Parlar-50 were positively associated with DHEA. Oxychlordan, *trans*-
302 nonachlor, *cis*-HCE, and Mirex were inversely associated with the androstenedione-
303 DHEA ratio. Oxychlordan, *cis*-nonachlor, *trans*-nonachlor, dieldrin, *cis*-HCE, HCB,
304 Mirex, and Parlar-50 showed inverse associations with the testosterone-androstenedione
305 ratio. Both *trans*-nonachlor and Mirex were inversely associated with cortisol and
306 cortisone. Oxychlordan, *cis*-nonachlor, *trans*-nonachlor, *cis*-HCE, Mirex, and Parlar-
307 50 were positively associated with the adrenal androgen-glucocorticoid ratio. β -HCH
308 was inversely associated with SHBG, and β -HCH, Mirex, Parlar-26, and Parlar-50 were
309 positively associated with FSH. *o,p'*-DDE, *p,p'*-DDE, *o,p'*-DDT, *p,p'*-DDT, dieldrin, β -
310 HCH, Mirex, and Parlar-50 were all inversely associated with prolactin. Finally, *cis*-
311 nonachlor, *p,p'*-DDE, *p,p'*-DDT, *cis*-HCE, HCB, β -HCH, Mirex, Parlar-26, and Parlar-
312 50 were inversely associated with the FSH-inhibin B ratio. There was no statistically
313 significant association between OCPs and progesterone, estradiol, androstenedione,
314 FSH, inhibin B, or INSL3. Among girls, *p,p'*-DDD was inversely associated with
315 DHEA and the adrenal androgen-glucocorticoid ratio, and was positively associated

with cortisone. There was no association between OCPs and progesterone, estradiol, testosterone, androstenedione, cortisol, SHBG, or prolactin among girls.

Figure 1 shows the relationships between hormones and OCPs in quartile models for boys (only in cases where $P < 0.05$ was observed). Testosterone showed a decreasing trend in relation to quartiles of Mirex, while LSM analysis of the estradiol-testosterone ratio showed an increasing trend of p,p' -DDE in relation to quartiles. DHEA showed increasing trends in relation to the quartiles of *cis*-Nonachlor, Dieldrin, Parlar-26, and Parlar-50. Moreover, the LSM method showed that the 4th quartile of *cis*-nonachlor was significantly increased compared to the 1st quartile *cis*-nonachlor. LSM analysis of the testosterone-androstenedione ratio showed decreasing trends in relation to *cis*-nonachlor, *trans*-nonachlor, Dieldrin, Mirex, and Parlar-50. Moreover, LSM analysis of the adrenal androgen-corticoid ratio showed an increasing trend of *cis*-nonachlor, Parlar-26, and Parlar-50, while SHBG showed a decreasing trend of β -HCH. Prolactin showed decreased trends of p,p' -DDE and o,p' -DDT. Statistically significant relationships between hormones and OCPs in the quartile models were not found among girls.

4. Discussion

In linear models, we found that relatively low levels of OCPs were inversely associated with testosterone, cortisol, cortisone, SHBG, and prolactin, but positively associated with DHEA in newborn boys after stratification by sex. Positive associations between OCPs and each of estradiol-testosterone and adrenal androgen-glucocorticoid, as well as an inverse association between OCPs and each of androstenedione-DHEA, testosterone-androstenedione, corticoid-cortisone, and the FSH-inhibin B ratio, were also observed

among boys. In quartile models, testosterone was inversely associated with OCPs, whereas DHEA was positively associated with them. The estradiol-testosterone and adrenal androgen-glucocorticoid ratios tended to increase when OCP concentrations were the higher quartile, while the testosterone-androstenedione ratio tended to decrease. SHBG and prolactin showed inverse associations with OCPs. Among girls, *p,p'*-DDD was inversely associated with DHEA levels and positively associated with levels of cortisol; it was also inversely associated with the glucocorticoid-adrenal androgen ratio. However, these associations were not observed in the quartile models, which would have provided more credence to the findings of the linear models. Overall, our data suggested that the natures of the associations between OCP and hormones differ according to sex, and that clear associations were observed only among infant boys.

The levels of OCPs in maternal blood have been measured in several studies performed in various countries. In this study, the median *p,p'*-DDE value in maternal whole blood was 619.26 pg/g-wet. In a study in Chiapas, Mexico, the median values of DDT and DDE in maternal serum collected in 2002–2003 were 1.9 and 19.5 µg/L, respectively (Longnecker et al. 2007). A study of Mexican-Americans in the US state of California found that the maternal geometric mean values of *p,p'*-DDT, *o,p'*-DDT, and *p,p'*-DDE were 22.0, 1.8, and 1436.9 ng/g-lipid, respectively (Eskenazi et al. 2006). A study in China showed geometric means of *p,p'*-DDE, HCB, and β-HCH in maternal serum, at 203.54 ng/g, 70.62 ng/g, and 67.67 ng/g, respectively (Guo et al. 2014). In another recent study in South Africa, the median maternal *p,p'*-DDE level was 241.3 ng/g lipids (Bornman et al. 2016). A meta-analysis of 12 European cohorts found that the median cord serum *p,p'*-DDE concentration was 527.9 ng/L (ranging from 49.8

ng/L to 1208 ng/L in various studies) (Govarts et al. 2012). By using Govarts et al.'s conversion factor to calculate cord serum levels from maternal whole blood levels in our study (cord serum level = $0.36 \times$ maternal whole blood level), the estimated median level of *p,p'*-DDE in the cord serum of our study was 229.1 ng/L, which is approximately half the median value of European cohorts. Taken together, the OCP exposure levels in our cohort were relatively low in comparison.

Only 1 study, performed in France, examined prenatal OCP exposure and hormone levels at birth (Warembourg et al. 2016). The investigators found that higher levels of HCB and HCE were associated with reduced levels of testosterone and elevated levels of SHBG among boys. HCE was also associated with higher levels of estradiol and a lower testosterone-estradiol ratio among girls. There was no association between *p,p'*-DDE and any hormone levels. Their results were partly consistent with ours. In our study, OCPs including HCB and HCE showed inverse associations with testosterone; these were not significant except for Mirex among boys. Although we did not find any association between estradiol and OCPs, their levels tracked together in a manner also observed by Warembourg et al. (2016). Moreover, the positive association between the estradiol-testosterone ratio and OCPs, which was statistically significant for *p,p'*-DDE in this study, are consistent with the findings of Warembourg et al. (2016), as is the significant decrease in the aromatase index (testosterone/estradiol) with increasing HCE. On the other hand, SHBG had a significant inverse correlation with Mirex in our study; which was in direct contrast to Warembourg et al.'s findings; we are unable to explain this discrepancy, as the sampling period (2002–2006) and sample sizes ($n=282$ for their study and $n=232$ for ours) were comparable. Additionally, the exposure levels of DDE, HCE, and HCB in our study and in that of Warembourg et al. were

comparable. However, the detection rates of HCB and HCE were higher in our study, and Warembourg et al. did not measure chlordanes, Mirex, or toxaphenes. Because of the low detection percentage, Warembourg et al. divided OCP levels into two or three categories to examine the association of each with hormones; this could explain why their results do not match ours more closely. We found no other studies that investigated associations between OCPs and DHEA, androstenedione, cortisol, or cortisone. More studies are therefore warranted to ascertain the association between OCPs and steroidogenesis at birth.

In this study, DDT, DDE, and DDD were not associated with steroid hormones except for *p,p'*-DDE, which showed a positive association with the estradiol-testosterone ratio in boys. The increased estradiol-testosterone ratio suggested increased CYP19A1 enzyme activity. A previous animal study showed that *p,p'*-DDE induces CYP19A1 in hepatic microsomal samples of adult male rats (You et al. 2001), which is consistent with our results. In girls, *p,p'*-DDD was inversely associated with DHEA and the adrenal androgen-glucocorticoid ratio, but was positively associated with cortisone levels. However, these associations were not observed in the quartile models; therefore, false positive associations are likely. Longnecker et al. (2007) conducted a study in Mexico where maternal DDT levels are relatively high, and found no evidence that in utero exposure to DDE was related to anogenital distance or penile dimensions at birth among male infants. Additionally, Bornman et al. (2016) conducted a similar study in South Africa and reported no associations between *p,p'*-DDT/-DDE or *o,p'*-DDT and anogenital distance measurements at birth in either boys or girls. Yet another study in Denmark found no association between prenatal *p,p'*-DDE levels and reproductive hormones at approximately 20 years of age (Vested et al. 2014). Taken together, these

data indicate that DDTs may not alter infant steroid hormones at the levels detected in these studies.

Among boys, *p,p'*-DDE and *o,p'*-DDT were inversely associated with prolactin in quartile models. Although there have been no specific studies of the mechanisms of OCP influence on prolactin, other investigations suggest that newborns with lower levels of prolactin in their cord blood are more likely to have an increased risk of respiratory distress syndrome than those with higher levels of prolactin (Parker et al. 1989; Padvi et al. 2017). Combined with data from the Canadian Health Measures Survey that DDT exposure is inversely associated with lung function parameters in adults (Ye et al. 2015), long term follow-up of children who were exposed to these chemicals is needed to clarify the health-related consequences of such exposure.

Studies of OCPs other than DDTs are scarce. We found that *cis/trans*-nonachlor, Dieldrin, Mirex, and toxaphenes (Parlar-26 and 50) were positively associated with DHEA as well as with the adrenal androgen-glucocorticoid ratio, but were inversely associated with testosterone, the testosterone-androstenedione ratio, and prolactin in boys. Decreasing testosterone-androstenedione ratio trends suggests the downregulation of HSB17B1; previous animal studies have shown that aldrin inhibits HSB17B1 (Chatterjee et al. 1988), which is consistent with our findings. DHEA is the main precursor of sex hormones and cortisol antagonists (Mastorakos and Ilias 2003). The increasing adrenal androgen-glucocorticoid ratio suggests that chlordanes, Dieldrin, Mirex, and toxaphenes may shift steroidogenesis towards androgenic hormones (C19-steroids), although we observed no evidence of this. However, circulating hormones are regulated by several cascade reactions. Translocation of cholesterol from the outer mitochondrial membrane to the inner membranes is a critical step in steroidogenesis;

this process is enhanced by steroidogenic acute regulatory protein (StAR), which is
 encoded by *STARD1*. Other key human steroidogenic genes are *CYP11A1*, *CYP17A1*,
CYP11B1/CYP11B2, *CYP21A2*, *SRD5A1*, and *SRD5A2*. Moreover, *SULT2A1* and
SULT2B1 encode enzymes that convert DHEA to DHEA-sulfate and vice versa.
 Although we have not measured methoxychlor, another synthetic organochlorine
 insecticide and a derivative of DDT showed decreased expression of CYP19A1,
 HSD17B1, *CYP17A1*-encoded cytochrome P450 family 17 subfamily A member 1,
 HSD3B1, *CYP11A1*-encoded cytochrome P450 family 11 subfamily A member 1, and
 StAR, but increased expression of *CYP11B1*-encoded cytochrome P450 family 1
 subfamily B member 1 enzyme levels, *in vitro* (Basavarajappa et al. 2011; Vaithinathan
 et al. 2008). Therefore, our overall findings do not rule out that many of the OCPs
 measured in this study may alter steroid hormones by inhibiting such steroidogenesis
 enzymes. Moreover, a previous study notably examined 15 organochlorines (OCs)
 mixture similar to those found in the bladders of Arctic ringed seals. Exposing male rats
in utero to this OC mixture caused disruptions in the development of androgen-
 dependent organs such as the testis, epididymis, seminal vesicle, and prostate (Anas et
 al. 2005). They also investigated that OC mixture's direct inhibition of Leydig cell
 steroidogenesis by disrupting cholesterol transport into the mitochondria via decreasing
 StAR protein levels, and by converting cholesterol into pregnenolone by modulating
 adrenodoxin reductase and CYP11A1 proteins (Enangue Njembele et al. 2014). We
 speculate that different OCPs influence steroidogenesis similarly. Additional studies on
 altered steroidogenic and metabolic enzymes with different OCPs are required to test
 these hypotheses.

1181
1182
1183
1184
1185 459 In our linear regression model, HCH, Mirex, and toxaphenes were positively
1186
1187 460 associated with FSH, as was the FSH-inhibin B ratio. Sertoli cells secrete inhibin B,
1188
1189 461 which was first identified by its ability to negatively regulate FSH (Carlson et al. 2009).
1190
1191 462 Increasing levels of FSH together with the FSH-inhibin B ratio point to a negative
1192
1193 463 feedback mechanism as well as the influence of OCPs on Sertoli cells. However, these
1194
1195 464 associations were not statistically significant in our quartile model; hence, the effects of
1196
1197 465 OCPs on Sertoli cells remain unclear.

1200 466 Our study found a significant association between OCPs and hormones only
1201
1202 467 among boys. Although the reason for this remains unclear, one possible explanation for
1203
1204 468 this sex preference is that most OCPs have an affinity for hormone receptors including
1205
1206 469 androgen receptor, estrogen receptor, and/or aryl hydrocarbon receptor (Mnif et al.
1207
1208 470 2011; Kojima et al., 2004). Thus, OCPs may mimic or block the natural hormone's
1209
1210 471 action (as an agonist or antagonist, respectively), and can interfere with the synthesis,
1211
1212 472 transport, metabolism, and elimination of hormones (Mnif et al. 2011). Estrogen and
1213
1214 473 androgen receptors are primarily involved in sexual differentiation and reproduction
1215
1216 474 (Busillo et al. 2009). While estrogens and progestins are essential for normal female
1217
1218 475 development, androgens are involved in various aspects of male reproductive
1219
1220 476 physiology. One animal study showed that *p,p'*-DDE inhibits androgen binding to the
1221
1222 477 AR, androgen-induced transcriptional activity, and androgen action in developing
1223
1224 478 (Kelce W.R., et al., 1995). Androgen receptors are expressed in variety of tissues, but
1225
1226 479 their levels differed in human fetal tissues (Wilson and McPhaul, 1996). During fetal
1227
1228 480 genital development, the female phenotype is considered to be the baseline (or default)
1229
1230 481 condition, and the development of maleness requires additional secretions produced by
1231
1232 482 the testis (Carlson 2009). Thus, we speculate that the effect of anti-androgenic activities
1233
1234
1235
1236
1237
1238
1239

of OCPs on males is more severe than the effect of their estrogenic activities on females. The physiological differences in the roles of these hormones may explain the observation of sex differences in OCP-hormone associations. One epidemiological study in Mexico found that higher exposure to *p,p'*-DDE *in utero* shortened the anal position index among boys but not among girls (Torres-Sanchez et al., 2008). The authors explained that this was due to the putative androgen deficiency occurring due to the reduction of transcriptional activity that occurs when AR is blocked by *p,p'*-DDE *in utero*. Although the exposure levels in Torres-Sanchez et al.'s study were 10 times higher than that in ours, our results were in line with those of their study. In vitro reporter gene assays showed that not only *p,p'*-DDE, but also other DDTs, dieldrin, and heptachlors showed AR antagonist effects (Kojima et al., 2004). Hence, we assume that those OCPs studied herein with AR antagonist properties share similar modes of action in terms of male-specific responses.

The strength of this study is that we examined a wide range of OCPs. Investigating seven steroids enabled us to construct a clearer picture of the association between steroidogenesis and OCPs levels. Measuring steroid hormones by LC-MSMS is considered more accurate than other methods such as radioimmunoassays, which is another strength of this study. However, there are several limitations as well. First, the 15 OCPs are moderately-to-highly correlated with each other (Spearman's rho: 0.230–0.918, $P < 0.001$). Thus, we were unable to clarify the effect of individual OCPs on hormones. Moreover, there may be other residual confounding factors. Previous studies suggested that reproductive hormones in cord blood may be affected by factors such as diurnal variation, duration of labor, placental weight, and the presence of pre-eclampsia (Hollier et al. 2014; Keelan et al. 2012). A recent cross-sectional study among adults

suggested an association between OCP concentrations and total cholesterol levels (Arrebola et al. 2014), which may also modify steroid hormones levels. Second, multiple tests of 15 OCPs and 13 hormones may have found statistically significant associations by chance. However, the associations between OCPs and hormones exhibited consistent trends, which suggest that the results are robust and that OCP exposure is likely to alter infants' hormones in utero. Finally, there is a possibility of selection bias in this study, as only participants with available cord blood samples were included in the analysis. Because the life and the safety of the mother and child were of utmost priority, cord blood samples were seldom acquired during Caesarian sections. Thus, two infants were delivered Caesarian sections and others included in this study were delivered vaginally; they had longer gestational ages and heavier birth weights than the infants who were excluded, which indicated that the analysis was biased towards healthier infants. Therefore, the effects of OCPs may have been underestimated in this study.

5. Conclusion

We found that exposure to relatively low levels of OCPs such as *cis/trans*-nonachlor, *p,p'*-DDE, *o,p'*-DDT, Dieldrin, β -HCH, Mirex, and toxaphenes *in utero* was significantly associated with levels of hormones and their ratios in male fetuses. These results suggest that OCPs that include but are not limited to DDTs ought to be examined, as the existing data are limited. Disrupting the balance of steroid hormones may cause adverse effects on reproductive growth, development, and other health outcomes in later life. The clinical significance of these findings is unclear at present, as it remains unknown whether these small hormonal alterations are of any future health

consequences in these individuals. Therefore, further studies investigating the long-term effects of OCP exposure are required.

Acknowledgements

We would like to thank the mothers and children who participated in the study, as well as all the staff at the Sapporo Toho Hospital. This study was supported in part by the Japan Ministry of Health, Labour and Welfare; the Environment Research and Technology Development Fund (5C-1252 and 5-1554); and Grants in Aid of Scientific Research from the Japan Society for the Promotion of Science, the Ministry of Education, Culture, Sports, Science, and Technology (13307015, 16209022, 19209024, 22249021, 26740028, and 26670321).

References

- Araki, A., Mitsui, T., Miyashita, C., Nakajima, T., Naito, H., Ito, S., Sasaki, S., Cho, K., Ikeno, T., Nonomura, K., Kishi, R., 2014. Association between maternal exposure to di(2-ethylhexyl) phthalate and reproductive hormone levels in fetal blood: the hokkaido study on environment and children's health. PLoS One. 9, e109039.
- Araki, A., Mitsui, T., Goudarzi, H., Nakajima, T., Miyashita, C. Itoh, S., Sasaki, S., Cho, K., Moriya, K., Shinohara, N., Nonomura, K., Kishi, R., 2017. Prenatal di(2-ethylhexyl) phthalate exposure and disruption of adrenal androgens and glucocorticoids levels in cord blood: The Hokkaido Study. Sci. Total Environ. 581–582, 297–304.
- Arrebola, J.P., Ocana-Riola, R., Arrebola-Moreno, A.L., Fernandez-Rodríguez, M., Martin-Olmedo, P., Fernandez, M.F., Olea, N., 2014. Associations of accumulated exposure to persistent organic pollutants with serum lipids and obesity in an adult cohort from Southern Spain. Environ Pollut. 195, 9-15.
- Anas, MK.I., Guillemette, C., Ayotte, P., Pereg, D., Giguère, F., Bailey, J.L., 2005. In Utero and Lactational Exposure to an Environmentally Relevant Organochlorine Mixture Disrupts Reproductive Development and Function in Male Rats. Biol. Reprod, 73, 14-426.
- Basavarajappa, M.S., Craig, Z. R., Hernández-Ochoa, I., Paulose, T., Leslie, T.C., Flaus, J. A., 2011. Methoxychlor reduces estradiol levels by altering steroidogenesis and metabolism in mouse antral follicles in vitro. Toxicol Appl Pharmacol, 253, 161-169.
- Bernard, L., Martinat, N., Lécureuil, C., Crépieux, P., Reiter, E., Tilloy-Ellul, A., Chevalier, S., Guillou, F., 2007. Dichlorodiphenyltrichloroethane impairs follicle-

stimulating hormone receptor-mediated signaling in rat Sertoli cells. *Reprod. Toxicol.* 23, 158–164.

Bornman, M.S., Chevrier, J., Rauch, S., Crause, M., Obida, M., Sathyanarayana, S., Barr, D.B., Eskenazi, B., 2016. Dichlorodiphenyltrichloroethane exposure and anogenital distance in the Venda Health Examination of Mothers, Babies and their Environment (VHEMBE) birth cohort study, South Africa. *Andrology*. 4, 608–615.

Braun, T., Challis, J.R., Newnham, J.P., Sloboda, D.M., 2013. Early-life glucocorticoid exposure: the hypothalamic-pituitary-adrenal axis, placental function, and long-term disease risk. *Endocr. Rev.* 34, 885–916.

Busillo, J. M., Rhen, T., Cidlowski, J.A., 2009. Chapter 5 Steroid Hormone Action, in: Strauss III, J.F., Barbieri, R.L. (Eds.), *Yen and Jaffe’s Reproductive Endocrinology, Physiology, Pathophysiology, and Clinical Management*, 6th edition. Elsevier, Philadelphia, PA, USA, pp. 105-120.

Carlson, B.M., 2009. Fourth Edition, *Human Embrology and Developmental Biology*. Elsevier, Philadelphia, PA, USA.

Chatterjee, S., Ray, A., Bagchi, P., Deb, C., 1988. Suppression of testicular steroidogenesis in rats by the organochlorine insecticide Aldrin. *Environ. Pollut.* 51, 87–94.

Ministry of Environment, 2006. Available at: https://www.env.go.jp/chemi/anzen/c_guidebook_h18/01.pdf [accessed 25 May 2017].

- Enangue Njembele, A.N., Bailey, J.L., Tremblay, J.J., 2014. In Vitro Exposure of Leydig Cells to an Environmentally Relevant Mixture of Organochlorines Represses Early Steps of Steroidogenesis¹. *Biol Reprod.*, 90, 1-10.
- Eskenazi, B., Marks, A.R., Bradman, A., Fenster, L., Johnson, C., Barr, D.B., Jewell, N.P., 2006. In utero exposure to dichlorodiphenyltrichloroethane (DDT) and dichlorodiphenyldichloroethylene (DDE) and neurodevelopment among young Mexican American children. *Pediatrics*. 118, 233–241.
- Freire, C., Koifman, R.J., Sarcinelli, P.N., Rosa, A.C., Clapauch, R., Koifman, S., 2014. Association between serum levels of organochlorine pesticides and sex hormones in adults living in a heavily contaminated area in Brazil. *Int. J. Hyg. Environ. Health*. 217, 370–378.
- Goudarzi, H., Araki, A., Itoh, S., Sasaki, S., Miyashita, C., Mitsui, T., Nakazawa, H., Nonomura, K., Kishi, R., 2017. The association of prenatal exposure to perfluorinated chemicals with glucocorticoid and androgenic hormones in cord blood samples: The Hokkaido Study. *Environ. Health Perspect.* 125, 111–118.
- Govarts, E., Nieuwenhuijsen, M., Schoeters, G., Ballester, F., Bloemen, K., de Boer, M., Chevrier, C., Eggesbø, M., Guxens, M., Krämer, U., Legler, J., Martínez, D., Palkovicova, L., Patelarou, E., Ranft, U., Rautio, A., Petersen, M.S., Slama, R., Stigum, H., Toft, G., Trnovec, T., Vandentorren, S., Weihe, P., Kuperus, N.W., Wilhelm, M., Wittsiepe, J., Bonde, J.P.; Obelix., ENRIECO, 2012. Birth weight and prenatal exposure to polychlorinated biphenyls (PCBs) and dichlorodiphenyldichloroethylene (DDE): A meta-analysis within 12 European birth cohorts. *Environ. Health Perspect.* 120, 162–170

- 611 Guo, H., Jin, Y., Cheng, Y., Leaderer, B., Lin, S., Holford, T.R., Qiu, J., Zhang, Y., Shi,
612 K., Zhu, Y., Niu, J., Bassig, B.A., Xu, S., Zhang, B., Li, Y., Hu, X., Chen, Q.,
613 Zheng, T., 2014. Prenatal exposure to organochlorine pesticides and infant birth
614 weight in China. *Chemosphere*. 110, 1–7.
- 615 Haugen, T.B., Tefre, T., Malm, G., Jönsson, B.A., Rylander, L., Hagmar, L., Bjørsvik,
616 C., Henrichsen, T., Sæther, T., Figenschau, Y., Giwercman, A., 2011. Differences
617 in serum levels of CB-153 and p,p'-DDE, and reproductive parameters between
618 men living south and north in Norway. *Reprod. Toxicol.* 32, 261–267.
- 619 Hicks, R.A., Yee, J.K., Mao, C.S., Graham, S., Kharrazi, M., Lorey, F., Lee, W.P.,
620 2014. Precursor-to-product ratios reflect biochemical phenotype in congenital
621 adrenal hyperplasia. *Metabolomics*. 10, 123–131.
- 622 Hollier, L.P., Keelan, J.A., Hickey, M., Maybery, M.T., Whitehouse, A.J., 2014.
623 Measurement of androgen and estrogen concentrations in cord blood: accuracy,
624 biological interpretation, and applications to understanding human behavioral
625 development. *Front. Endocrinol.* 5, 64.
- 626 Ivell, R., Wade, J.D., Anand-Ivell, R., 2013. INSL3 as a biomarker of Leydig cell
627 functionality. *Biol. Reprod.* 88, 1–8.
- 628 Jusko, T.A., Klebanoff, M.A., Brock, J.W., Longnecker, M.P., 2012. In-utero exposure
629 to dichlorodiphenyltrichloroethane and cognitive development among infants and
630 school-aged children. *Epidemiology*. 23, 689–698.
- 631 Kanazawa, A., Miyasita, C., Okada, E., Kobayashi, S., Washino, N., Sasaki, S.,
632 Yoshioka, E., Mizutani, F., Chisaki, Y., Saijo, Y., Kishi, R., 2012. Blood
633 persistent organochlorine pesticides in pregnant women in relation to physical and

- 634 environmental variables in The Hokkaido Study on Environment and Children's
- 635 Health. *Sci. Total Environ.* 426, 73–82.
- 636 Keelan, J.A., Mattes, E., Tan, H., Dinan, A., Newnham, J.P., Whitehouse, A.J., Jacoby,
- 637 P., Hickey, M., 2012. Androgen concentrations in umbilical cord blood and their
- 638 association with maternal, fetal and obstetric factors. *PLoS One* 7, e42827
- 639 Kelce, W.R., Stone, C. R., Laws, S. C., Gray, L.E., Kemppainen J.A., Wislson, E.M.,
- 640 1995. Persistent DDT metabolite p,p'-DDE is a potent androgen receptor
- 641 antagonist. *Nature*, 375, 581-585.
- 642 Kishi, R., Araki, A., Minatoya, M., Hanaoka, T., Miyashita, C., Itoh, S., Kobayashi, S.,
- 643 Ait Bamai, Y., Yamazaki, K., Miura, R., Tamura, N., Ito, K., Goudarzi H.,
- 644 Members of The Hokkaido Study on Environment and Children's Health, 2017.
- 645 The Hokkaido Birth Cohort Study on Environment and Children's Health: cohort
- 646 profile—updated 2017. *Environ. Health Prev. Med.* 22, 46–62.
- 647 Kishi, R., Kobayashi, S., Ikeno, T., Araki, A., Miyashita, C., Itoh, S., Sasaki, S., Okada,
- 648 E., Kobayashi, S., Kashino, I., Itoh, K., Nakajima, S.; Members of the Hokkaido
- 649 Study on Environment and Children's Health, 2013. Ten years of progress in the
- 650 Hokkaido birth cohort study on environment and children's health: cohort
- 651 profile—updated 2013. *Environ. Health Prev. Med.* 18, 429–450.
- 652 Kishi, R., Sasaki, S., Yoshioka, E., Yuasa, M., Sata, F., Saijo, Y., Kurahashi, N.,
- 653 Tamaki, J., Endo, T., Sengoku, K., Nonomura, K., Minakami, H.; Hokkaido Study
- 654 on Environment and Children's Health, 2011. Cohort profile: the Hokkaido Study
- 655 on Environment and Children's Health in Japan. *Int. J. Epidemiol.* 40, 611–618.

- 656 Kojima, H., Katsura, E., Takeuchi, S., Niiyama, K., Kobayashi, K., 2004. Screening for
657 estrogen and androgen receptor activities in 200 pesticides by in vitro reporter
658 gene assays using Chinese hamster ovary cells. 112, 524-531.
- 659 Kuiri-Hänninen, T., Sankilampi, U., Dunkel, L., 2014. Activation of the hypothalamic-
660 pituitary-gonadal axis in infancy: minipuberty. *Horm. Res. Paediatr.* 82, 73–80.
- 661 Labrie, F., Luu-The, V., Labrie, C., Simard, J., 2001. DHEA and its transformation into
662 androgens and estrogens in peripheral target tissues: intracrinology. *Front.*
663 *Neuroendocrinol.* 22, 185–212.
- 664 Longnecker, M.P., Gladen, B.C., Cupul-Uicab, L.A., Romano-Riquer, S.P., Weber, J.P.,
665 Chapin, R.E., Hernández-Avila, M., 2007. In utero exposure to the antiandrogen
666 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE) in relation to anogenital
667 distance in male newborns from Chiapas, México. *Am. J. Epidemiol.* 165, 1015–
668 1022.
- 669 Mastorakos G, Ilias I. 2003. Maternal and fetal hypothalamic-pituitary-adrenal axes
670 during pregnancy and postpartum. *Ann NY Acad Sci* 997:136–149.
- 671 Mnif, W., Ibn Hadj Hassin, A., Bouaziz, A., Bartegi, A., Thomas, O., Roig, B., 2011.
672 Effect of Endocrine Disruptor Pesticides: A Review. *Int. J. Environ. Res. Public*
673 *Health* 8, 2265-2303.
- 674 Padvi, N.V., Narkhede, H.R., Pawar A.P., Mhatre, P.N., 2017. Prolactin level in
675 umbilical cord blood of newborn and its relation to respiratory distress syndrome.
676 *Int. J. Reprod. Contracept. Obstet. Gynecol.* 6, 433-438.
- 677 Parker Jr., C.R., MadDonald, P.C., Guzick, D.S., Porter, J.C., Rosenfeld, C.R., Hauth,
678 J.C., 1989. Prolactin levels in umbilical cord blood of human infants: Relation to

679 gestational age, maternal complications, and neonatal lung function. *Am J Obstet*
 680 *Gynecol.* 161, 7950-802.
 681 Orth, J.M., Boehm, R., 1990. Functional coupling of neonatal rat Sertoli cells and
 682 gonocytes in coculture. *Endocrinology.* 127, 2812–2820.
 683 Reynolds, R.M., 2010. Corticosteroid-mediated programming and the pathogenesis of
 684 obesity and diabetes. *J. Steroid. Biochem. Mol. Biol.* 122, 3–9.
 685 Rignell-Hydbom, A., Rylander, L., Giwercman, A., Jönsson, B.A., Nilsson-Ehle, P.,
 686 Hagmar, L., 2004. Exposure to CB-153 and p,p'-DDE and male reproductive
 687 function. *Hum. Reprod.* 19, 2066–2075.
 688 Strauss III, J. F., Chapter 4 The synthesis and Metabolism of Steroid Hormones, in:
 689 Strauss III, J.F., Barbieri, R.L. (Eds.), *Yen and Jaffe's Reproductive*
 690 *Endocrinology, Physiology, Pathophysiology, and Clinical Management*, 6th
 691 edition. Elsevier, Philadelphia, PA, USA, pp. 105-120.
 692 The United Nations Environment Programme (UNEP) and World Health Organization
 693 (WHO), 2012. State of the science of endocrine disrupting chemicals. Edited by
 694 Åke Bergman, Jerrold J. Heindel, Susan Jobling, Karen A. Kidd and R. Thomas
 695 Zoeller. World Health Organization Press, Geneva. Available at
 696 http://www.who.int/iris/bitstream/10665/78101/1/9789241505031_eng.pdf?ua=1
 697 [accessed 25 May 2017].
 698 The United Nations Environment Programme (UNEP). Available at
 699 <http://chm.pops.int/default.aspx> [accessed 25 May 2017].
 700 Torres-Sanchez, L., Zepeda, M., Cebrián, M.E., Belkind-Gerson, J., Garcia-Hernandez,
 701 R.M., Belkind-Valdovinos, U., López-Carrillo, L., 2008.
 702 Dichlorodiphenyldichloroethylene Exposure during the First Trimester of







1830
1831
1832
1833
1834 703 Pregnancy Alters the Anal Position in Male Infants. *Ann N Y Acad Sci*, 1140,
1835
1836 704 155-162.
1837
1838
1839 705 Vaithinathan, S., Saradha, B., Mathur, P.P., 2008. Transient inhibitory effect of
1840
1841 706 methoxychlor on testicular steroidogenesis in rat: an in vivo study. *Arch. Toxicol.*
1842
1843 707 82, 833–839.
1844
1845 708 Vested, A., Ramlau-Hansen, C.H., Olsen, S.F., Bonde, J.P., Støvring, H., Kristensen,
1846
1847 709 S.L., Halldorsson, T.I., Rantakokko, P., Kiviranta, H., Ernst, E.H., Toft, G., 2014.
1848
1849 710 In utero exposure to persistent organochlorine pollutants and reproductive health
1850
1851 711 in the human male. *Reproduction*. 148, 635–646.
1852
1853 712 Warembourg, C., Debost-Legrand, A., Bonvallot, N., Massart, C., Garlantézec, R.,
1854
1855 713 Monfort, C., Gaudreau, E., Chevrier, C., Cordier, S., 2016. Exposure of pregnant
1856
1857 714 women to persistent organic pollutants and cord sex hormone levels. *Hum.*
1858
1859 715 *Reprod.* 31, 190–198.
1860
1861 716 Wilson, C.M. McPhaul, M.J., 1996. A and B forms of the androgen receptor are
1862
1863 717 expressed in a variety of human tissues. *Mol Cell Endocrinol*, 120, 51-57.
1864
1865 718 Windham, G.C., Lee, D., Mitchell, P., Anderson, M., Petreas, M., Lasley, B., 2005.
1866
1867 719 Exposure to organochlorine compounds and effects on ovarian function.
1868
1869 720 *Epidemiology*. 16, 182–190.
1870
1871 721 Yamashita, K., Okuyama, M., Watanabe, Y., Honma, S., Kobayashi, S., Numazawa,
1872
1873 722 M., 2007a. Highly sensitive determination of estrone and estradiol in human
1874
1875 723 serum by liquid chromatography–electrospray ionization tandem mass
1876
1877 724 spectrometry. *Steroids*. 72, 819–827.
1878
1879
1880 725 Yamashita, K., Takahashi, M., Tsukamoto, S., Numazawa, M., Okuyama, M., Honma,
1881
1882 S., 2007b. Use of novel picolinoyl derivatization for simultaneous quantification
1883
1884
1885
1886
1887
1888









1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947

727 of six corticosteroids by liquid chromatography-electrospray ionization tandem
728 mass spectrometry. *J. Chromatogr. A.* 1173, 120–128.
729 Ye, M., Beach, J., Martin, J.W., Senthilselvan, A., 2015. Association between Lung
730 Function in Adults and Plasma DDT and DDE Levels: Results from the Canadian
731 Health Measures Survey. *Environ. Health Perspect.* 123, 422-427.
732 You, L., Sar, M., Bartolucci, E., Ploch, S., Whitt, M., 2001. Induction of hepatic
733 aromatase by p,p'-DDE in adult male rats. *Mol. Cell Endocrinol.* 178, 207-214.
734

1948
1949
1950
1951
1952 735 Figure legends
1953
1954
1955 736
1956
1957 737 Fig. 1. Least square means (LSMs) of hormone levels according to maternal
1958
1959 738 organochlorine pesticide (OCP) concentration quartiles in boys. The X-axes show the
1960
1961 739 OCP quartiles, while the Y-axes show each hormone level calculated using the LSM in
1962
1963 740 the boxes; the error bars are the 95% confidence intervals. The four OCP categories
1964
1965 741 were, *cis*-nonachlor: Quartile 1 (Q1) (≤ 7.07 pg/g-wet), Q2 (7.08–10.37 pg/g-wet), Q3
1966
1967 742 (10.38–15.06 pg/g-wet), and Q4 (≥ 15.07 pg/g-wet); *trans*-nonachlor: Q1 (≤ 52.25 pg/g-
1968
1969 743 wet), Q2 (52.26–75.60 pg/g-wet), Q3 (52.26–75.60 pg/g-wet), and Q4 (≥ 110.29 pg/g-
1970
1971 744 wet); *p,p'*-DDE: Q1 (≤ 0.99 pg/g-wet), Q2 (1.00–1.65 pg/g-wet), Q3 (1.66–2.54 pg/g-
1972
1973 745 wet), and Q4 (≥ 2.55 pg/g-wet); *o,p'*-DDT: Q1 (≤ 2.28 pg/g-wet), Q2 (2.29–3.36 pg/g-
1974
1975 746 wet), Q3 (3.37–4.66 pg/g-wet), and Q4 (≥ 4.67 pg/g-wet); Dieldrin: Q1 (≤ 12.17 pg/g-
1976
1977 747 wet), Q2 (12.17–16.68 pg/g-wet), Q3 (16.69–22.05 pg/g-wet), and Q4 (≥ 22.06 pg/g-
1978
1979 748 wet); β -hexachlorocyclohexane (β -HCH): Q1 (≤ 104.33 pg/g-wet), Q2 (104.34–154.31
1980
1981 749 pg/g-wet), Q3 (154.32–238.06 pg/g-wet), and Q4 (≥ 238.07 pg/g-wet); Mirex: Q1 (≤ 4.12
1982
1983 750 pg/g-wet), Q2 (4.13–6.04 pg/g-wet), Q3 (6.05–8.52 pg/g-wet), and Q4 (≥ 8.53 pg/g-
1984
1985 751 wet); Parlar-26: Q1 (≤ 2.84 pg/g-wet), Q2 (2.85–4.46 pg/g-wet), Q3 (4.47–7.11 pg/g-
1986
1987 752 wet), and Q4 (≥ 7.12 pg/g-wet); and Parlar-50: Q1 (≤ 4.31 pg/g-wet), Q2 (4.31–6.56
1988
1989 753 pg/g-wet), Q3 (6.56–9.83 pg/g-wet), and Q4 (≥ 9.83 pg/g-wet). (A) Testosterone
1990
1991 754 according to Mirex, (B) Estradiol-testosterone ratio (E2/T) according to *p,p'*-
1992
1993 755 dichlorodiphenyldichloroethylene (DDE), (C) dehydroepiandrosterone (DHEA)
1994
1995 756 according to *cis*-nonachlor, (D) DHEA according to Dieldrin, (E) DHEA according to
1996
1997 757 Parlar-26, (F) DHEA according to Parlar-50, (G) Testosterone-androstenedione ratio
1998
1999 758 (T/Adione) according to *cis*-Nonachlor, (H) T/Adione according to *trans*-Nonachlor, (I)
2000
2001
2002
2003
2004
2005
2006

759 T/Adione according to Dieldrin, (J) T/Adione according to Mirex, (K) T/Adione
 760 according to Parlar-50, (L) Adrenal androgen-glucocorticoid ratio according to *cis*-
 761 Nonachlor, (M) Adrenal androgen-glucocorticoid ratio according to Parlar-26, (N)
 762 Adrenal androgen-glucocorticoid-ratio according to Parlar-50, (O) sex hormone-binding
 763 globulin (SHBG) according to β -HCH, (P) Prolactin according to *p,p'*-DDE, (Q)
 764 Prolactin according to *o,p'*-DDT. The first quartile is compared to the second, third, and
 765 fourth quartile OCPs as calculated using the Dunnett-Hsu method; the statistical
 766 significance of the *P* value was $*P<0.017$ based on Bonferroni's correction. LSMs were
 767 adjusted for maternal age, parity, and gestational age.
 768










Fig. 1.

Table 1 Maternal and infant characteristics

			This study (n=232)			Original cohort (n=514)		
			No.	%	Mean $\pm$ SD	No.	%	Mean $\pm$ SD
Mother								
Age at delivery (years)			232		30.45 $\pm$ 4.81	510		30.4 $\pm$ 4.9
Pre-pregnancy BMI (kg/m ²)			232		21.03 $\pm$ 2.92	506		21.2 $\pm$ 3.2
Educational level (years)	≤ 12		100	43.1		225	44.3	
	> 12		132	56.9		283	55.7	
Annual Household income (million yen per year)	< 5		166	71.6		345	68.3	
	≥ 5		66	28.4		160	31.7	
Smoking during pregnancy	No		190	81.9		404	79.7	
	Yes		42	18.1		103	20.3	
Alcohol consumption during pregnancy	No		154	66.4		351	69.1	
	Yes		78	33.6		157	30.9	
Parity	Primiparous		120	51.7		240	47.7	
	Multiparous		112	48.3		263	52.2	
Type of delivery	Vaginal		230	99.1		397	78.8	
	Caesarian section		2	0.9		107	21.2	
Blood sampling timing	During pregnancy		159	68.5		296	69.5	
	After delivery		73	31.5		130	30.5	
Infant								
Sex	Boys		106	45.7		246	48.1	
	Girls		126	54.3		265	51.9	
Birth weight (grams)			232		3130.5 $\pm$ 332.5	511		3025.6 $\pm$ 420.7
Gestational Age (weeks)			232		39.3 $\pm$ 1.1	511		38.9 $\pm$ 1.5
cryptorchidism			1	0.9		1	0.4	
hypospadias			0	0.0		0	0.0	

Table 2 Concentrations of organochlorine pesticides in maternal blood

Persistent organochlorine pesticides	Detection limit (pg/g-wet)	>DL (%)	Minimum	Percentile			Maximum
				25th	50th	75th	
Aldrin	1.00	0.4				<DL	12.83
Chlordanes							
oxychlordane	0.90	100.0	7.93	28.87	40.04	57.32	250.94
<i>cis</i> -Chlordane	0.70	62.1		<DL	1.15	2.29	17.53
<i>trans</i> -Chlordane	0.50	49.6			<DL	0.84	3.79
<i>cis</i> -Nonachlor	0.40	100.0	1.63	7.07	10.37	15.07	37.58
<i>trans</i> -Nonachlor	0.50	100.0	13.45	52.09	75.60	110.54	513.52
DDTs							
<i>o,p'</i> -DDD	0.50	14.2				<DL	1.16
<i>p,p'</i> -DDD	0.40	88.8	<DL	0.98	1.65	2.54	9.04
<i>o,p'</i> -DDE	0.40	86.6	<DL	0.72	1.25	1.78	4.60
<i>p,p'</i> -DDE	0.60	100.0	99.52	409.79	619.26	968.05	2686.23
<i>o,p'</i> -DDT	0.60	96.6	<DL	2.28	3.36	4.67	17.15
<i>p,p'</i> -DDT	0.40	100.0	2.38	16.22	23.17	33.94	104.76
Dieldrin	0.80	100.0	4.11	12.16	16.68	22.21	71.52
Endrin	1.00	0.0					<DL
Heptachlors							
Heptachlor	0.80	0.9				<DL	1.14
<i>trans</i> -HCE	1.00	0.0					<DL
<i>cis</i> -HCE	0.40	100.0	6.17	18.81	26.25	37.45	200.53
HCB	0.90	100.0	34.94	83.04	103.99	131.61	245.48
HCHs							
α -HCH	0.70	68.5		<DL	0.91	1.31	3.10
β -HCH	0.60	100.0	19.95	104.25	154.31	238.45	717.67
γ -HCH	0.90	57.3		<DL	1.09	1.73	100.92
δ -HCH	0.70	1.3				<DL	1.11
Mirex	0.50	100.0	0.88	4.11	6.04	8.53	30.11
Toxaphenes							
Parlar-26	1.00	97.0	<DL	2.84	4.46	7.13	20.82
Parlar-41	0.70	28.4			<DL	0.73	1.96
Parlar-40	2.00	0.9				<DL	2.43
Parlar-44	2.00	2.2				<DL	2.77
Parlar-50	2.00	96.1	<DL	4.30	6.56	9.86	29.29
Parlar-62	6.00	0.0					<DL

DL, detection limit; DDD, dichlorodiphenyldichloroethane; DDE, dichlorodiphenyldichloroethylene; DDT, dichlorodiphenyltrichloroethane; HCB, hexachlorobenzene; HCE, heptachlor epoxide; HCH, hexachlorocyclohexane.

Table 3 Distribution of steroids and reproductive hormones

Table 3. Distribution of Steroids and Reproductive Hormones																	
	DL	n	>DL (%)	Total (n=232)			Boys (n=106)					Girls (n=126)					P-value
				25%	Med	75%	n	>DL (%)	25%	Med	75%	n	>DL (%)	25%	Med	75%	
Steroid hormones																	
Progesterone (ng/mL)	0.01	232	100.0	177.381	219.036	278.019	106	100.0	184.087	224.121	280.633	126	100.0	169.619	216.065	276.129	0.460
Testosterone (pg/mL)	0.01	232	100.0	59.750	82.050	114.025	106	100.0	76.788	101.875	132.050	126	100.0	50.975	68.675	92.400	<0.001
Estradiol (ng/mL)	0.01	232	99.6	3.220	4.546	7.053	106	99.1	3.248	4.458	7.311	126	100.0	3.140	4.645	6.672	0.393
DHEA (ng/mL)	0.01	232	100.0	1.763	2.160	2.970	106	100.0	1.590	2.090	2.830	126	100.0	1.898	2.270	3.140	0.040
Androstenedione (ng/mL)	0.01	232	99.6	0.360	0.460	0.588	106	99.1	0.380	0.470	0.613	126	100.0	0.350	0.450	0.580	0.414
Cortisol (ng/mL)	0.25	232	98.7	22.808	41.485	65.258	106	99.6	22.415	41.065	66.213	126	98.4	24.725	42.455	63.953	0.773
Cortisone (ng/mL)	0.10	232	96.1	76.393	95.145	124.655	106	98.1	72.825	94.175	122.963	126	94.4	77.150	95.650	125.123	0.807
Steroid Hormone Binding Globulin (nmol/L)	1.10	232	99.6	13.500	15.700	18.875	106	100.0	13.575	16.200	19.300	126	99.2	13.300	15.450	18.425	0.239
Lutealizing Hormone (mIU/mL)	0.50	226	17.3			<DL	103	36.9		<DL	0.870	123	0.8			<DL	<0.001
Follicle Stimulating Hormone (mIU/mL)	0.50	225	22.2			<DL	103	48.5		<DL	0.660	122	0.0			<DL	<0.001
Inhibin B (pg/mL)	11	232	61.6	<DL	23.500	45.325	106	98.1	34.200	44.350	61.300	126	31.0		<DL	13.900	<0.001
Insulin-like factor 3 (ng/mL)	0.01	119	100.0	0.230	0.280	0.330	103	100.0	0.250	0.290	0.340	16	100.0	0.180	0.185	0.235	<0.001
Prolactin (ng/mL)	1.0	226	99.6	64.600	87.600	118.250	103	100.0	63.400	87.200	119.000	123	99.2	64.600	87.800	116.000	0.921

P values were calculated by Mann-Whitney U test;

DHEA, dehydroepiandrosterone; DL, detection limit

Table 4 Associations between OCPs exposure and steroid and reproductive hormone levels among boys

	Progesterone			Estradiol			Testosterone			Estradiol/Testosterone			DEHA			Androstenedione			Androstenedione/DHEA								
	β	95%CI		β	95%CI		β	95%CI		β	95%CI		β	95%CI		β	95%CI		β	95%CI							
Oxychlordan	-0.090	-0.416	0.236	0.007	-0.359	0.372	-0.176	-0.421	0.068	0.183	-0.140	0.505	0.243	0.028	0.459	*	0.006	-0.214	0.226	-0.238	-0.470	-0.005	*				
cis-Nonachlor	-0.149	-0.424	0.125	-0.005	-0.314	0.304	-0.095	-0.303	0.113	0.090	-0.184	0.363	0.247	0.066	0.427	**	0.070	-0.116	0.255	-0.177	-0.375	0.021	†				
trans-Nonachlor	-0.162	-0.436	0.112	-0.027	-0.335	0.282	-0.161	-0.367	0.045	0.134	-0.138	0.407	0.255	0.076	0.435	**	0.038	-0.147	0.224	-0.217	-0.413	-0.021	*				
p,p'-DDD	-0.097	-0.279	0.085	-0.151	-0.354	0.051	-0.065	-0.203	0.073	-0.086	-0.267	0.095	-0.023	-0.147	0.101		-0.016	-0.139	0.108	0.007	-0.126	0.141					
o,p'-DDE	-0.046	-0.234	0.143	0.050	-0.161	0.260	-0.029	-0.171	0.114	0.078	-0.108	0.265	0.080	-0.046	0.207		0.013	-0.114	0.140	-0.067	-0.204	0.069					
p,p'-DDE	0.034	-0.218	0.286	0.192	-0.088	0.472	-0.105	-0.295	0.084	0.297	0.054	0.541	*	0.108	-0.061	0.278		-0.041	-0.211	0.128	-0.150	-0.331	0.032				
o,p'-DDT	-0.056	-0.248	0.136	0.048	-0.167	0.263	-0.035	-0.180	0.110	0.083	-0.107	0.273		0.118	-0.010	0.246	†	0.010	-0.119	0.140	-0.108	-0.246	0.031				
p,p'-DDT	-0.077	-0.339	0.184	0.031	-0.262	0.324	-0.065	-0.263	0.132	0.096	-0.163	0.356		0.151	-0.024	0.325	†	0.016	-0.161	0.192	-0.135	-0.324	0.054				
Dieldrin	-0.178	-0.482	0.125	0.069	-0.273	0.410	-0.023	-0.254	0.208	0.092	-0.211	0.394		0.267	0.067	0.467	**	0.155	-0.048	0.359	-0.112	-0.333	0.109				
cis-HCE	-0.090	-0.416	0.236	0.007	-0.359	0.372	-0.176	-0.421	0.068	0.183	-0.140	0.505		0.243	0.028	0.459	*	0.006	-0.214	0.226	-0.238	-0.470	-0.005	*			
HCB	0.025	-0.438	0.489	0.114	-0.404	0.633	-0.139	-0.489	0.210	0.254	-0.203	0.711		0.311	0.004	0.619	*	0.058	-0.254	0.370	-0.253	-0.586	0.081				
β-HCH	0.118	-0.157	0.392	0.168	-0.139	0.474	-0.091	-0.299	0.117	0.259	-0.010	0.528	†	0.136	-0.049	0.320		-0.004	-0.190	0.181	-0.140	-0.339	0.059				
Mirex	-0.108	-0.418	0.203	-0.007	-0.355	0.342	-0.262	-0.492	-0.032	*	0.256	-0.050	0.561		0.213	0.007	0.420	*	-0.061	-0.270	0.149	-0.274	-0.494	-0.054	*		
Parlar-26	-0.124	-0.338	0.091	0.124	-0.116	0.364	0.002	-0.161	0.165	0.122	-0.090	0.335		0.235	0.097	0.373	**	0.100	-0.044	0.244	-0.135	-0.290	0.020	†			
Parlar-50	-0.099	-0.315	0.116	0.072	-0.170	0.313	-0.020	-0.183	0.144	0.091	-0.123	0.305		0.236	0.097	0.374	**	0.103	-0.041	0.248	-0.132	-0.288	0.023	†			
	Testosterone/Androstenedione			Cortisol			Cortisone			Cortisone/Cortisol			Adrenal androgen/Glucocorticoid			SHBG			Prolactin								
	β	95%CI		β	95%CI		β	95%CI		β	95%CI		β	95%CI		β	95%CI		β	95%CI							
Oxychlordan	-0.182	-0.339	-0.024	*	-0.363	-0.763	0.038	-0.398	-0.858	0.062	†	-0.035	-0.316	0.246	0.571	0.042	1.100	*	-0.082	-0.245	0.081	-0.077	-0.261	0.107			
cis-Nonachlor	-0.165	-0.297	-0.032	*	-0.218	-0.559	0.124	-0.310	-0.700	0.079		-0.092	-0.330	0.145	0.487	0.040	0.935	*	-0.040	-0.178	0.098	-0.150	-0.303	0.003	†		
trans-Nonachlor	-0.199	-0.330	-0.069	**	-0.372	-0.708	-0.036	*	-0.426	-0.810	-0.041	*	-0.054	-0.291	0.184	0.609	0.168	1.050	**	-0.027	-0.165	0.111	-0.075	-0.230	0.080		
p,p'-DDD	-0.049	-0.140	0.041		0.061	-0.166	0.289	0.014	-0.248	0.275		-0.048	-0.205	0.110	-0.049	-0.352	0.255		0.055	-0.036	0.146	0.021	-0.082	0.124			
o,p'-DDE	-0.042	-0.134	0.051		-0.108	-0.342	0.126	-0.148	-0.415	0.119		-0.040	-0.202	0.122	0.200	-0.109	0.510		-0.030	-0.124	0.064	-0.120	-0.224	-0.015	*		
p,p'-DDE	-0.064	-0.188	0.060		-0.290	-0.600	0.019	†	-0.249	-0.606	0.108		0.041	-0.176	0.258	0.354	-0.059	0.766	†	-0.080	-0.206	0.045	-0.226	-0.361	-0.092	**	
o,p'-DDT	-0.045	-0.140	0.049		-0.172	-0.410	0.065		-0.153	-0.426	0.120		0.019	-0.146	0.185	0.260	-0.055	0.574		-0.017	-0.114	0.079	-0.172	-0.275	-0.069	**	
p,p'-DDT	-0.081	-0.210	0.048		-0.073	-0.400	0.253		-0.192	-0.565	0.180		-0.119	-0.344	0.105	0.276	-0.155	0.707		-0.019	-0.150	0.112	-0.155	-0.299	-0.011	*	
Dieldrin	-0.178	-0.325	-0.032	*	0.028	-0.352	0.409		-0.207	-0.641	0.227		-0.235	-0.494	0.023	†	0.367	-0.134	0.867		-0.049	-0.202	0.103	-0.209	-0.377	-0.040	*
cis-HCE	-0.182	-0.339	-0.024	*	-0.363	-0.763	0.038	†	-0.398	-0.858	0.062	†	-0.035	-0.316	0.246	0.571	0.042	1.100	*	-0.082	-0.245	0.081	-0.077	-0.261	0.107		
HCB	-0.198	-0.424	0.028	†	-0.255	-0.830	0.321		-0.185	-0.845	0.476		0.070	-0.329	0.469	0.474	-0.289	1.236		-0.167	-0.397	0.062	-0.239	-0.495	0.017	†	
β-HCH	-0.087	-0.222	0.048		-0.153	-0.495	0.189		-0.076	-0.469	0.317		0.077	-0.160	0.314	0.221	-0.234	0.676		-0.147	-0.282	-0.012	*	-0.182	-0.332	-0.031	*
Mirex	-0.202	-0.350	-0.053	**	-0.588	-0.959	-0.218	**	-0.572	-1.002	-0.142	*	0.016	-0.252	0.285	0.744	0.249	1.239	**	-0.083	-0.238	0.073	-0.180	-0.352	-0.008	*	
Parlar-26	-0.098	-0.203	0.007	†	-0.174	-0.441	0.092		-0.289	-0.592	0.013	†	-0.115	-0.299	0.069	0.457	0.111	0.803	*	-0.017	-0.125	0.091	-0.107	-0.229	0.015	†	
Parlar-50	-0.123	-0.227	-0.019	*	-0.156	-0.424	0.111		-0.231	-0.537	0.075		-0.075	-0.260	0.111	0.418	0.069	0.767	*	-0.048	-0.156	0.060	-0.131	-0.252	-0.010	*	
	LH			FSH			Inhibin B			INSL3			T/LH			FSH/InhibinB											
	β	95%CI		β	95%CI		β	95%CI		β	95%CI		β	95%CI		β	95%CI										
Oxychlordan	0.037	-0.305	0.380		0.097	-0.143	0.337	-0.093	-0.301	0.115	-0.064	-0.190	0.063	-0.224	-0.684	0.236	0.190	-0.119	0.499								
cis-Nonachlor	0.087	-0.202	0.376		0.199	0.000	0.399	†	-0.140	-0.315	0.034	-0.015	-0.123	0.092	-0.185	-0.574	0.203	0.341	0.086	0.595	**						
trans-Nonachlor	0.077	-0.211	0																								

Adjusted regression coefficients (β) and 95% confidence intervals (CIs) for the association between a 10-fold increase of OCP and log10-transformed hormone levels as determined by a linear regression model

Each OCP was introduced into the model separately and adjusted for maternal age, parity, and gestational age.

*P < 0.05, **P < 0.01, †P < 0.1

Table 5 Associations between OCPs exposure and steroid and reproductive hormone levels among girls

	Progesterone			Estradiol			Testosterone			Estradiol/Testosterone			DEHA			Androstenedione						
	β	95%CI		β	95%CI		β	95%CI		β	95%CI		β	95%CI		β	95%CI					
Oxychlordane	0.136	-0.149	0.420	0.047	-0.175	0.270	0.050	-0.219	0.320	-0.003	-0.222	0.216	-0.087	-0.377	0.203	0.032	-0.189	0.254				
cis-Nonachlor	0.194	-0.069	0.456	0.019	-0.188	0.225	0.035	-0.215	0.284	-0.016	-0.220	0.187	-0.136	-0.404	0.132	0.006	-0.199	0.211				
trans-Nonachlor	0.192	-0.065	0.449	0.035	-0.167	0.237	0.065	-0.179	0.310	-0.030	-0.229	0.169	-0.163	-0.425	0.099	0.038	-0.163	0.239				
p,p'-DDD	0.099	-0.046	0.244	-0.059	-0.172	0.054	-0.041	-0.178	0.096	-0.018	-0.130	0.094	-0.160	-0.305	-0.014	*	-0.069	-0.181	0.043			
o,p'-DDE	-0.042	-0.212	0.127	-0.082	-0.214	0.049	-0.038	-0.198	0.122	-0.044	-0.174	0.086	0.000	-0.173	0.173	-0.066	-0.197	0.065				
p,p'-DDE	0.018	-0.201	0.237	-0.116	-0.285	0.054	0.035	-0.172	0.241	-0.151	-0.317	0.015	†	-0.156	-0.377	0.065	-0.077	-0.246	0.092			
o,p'-DDT	-0.071	-0.282	0.140	-0.109	-0.272	0.055	-0.024	-0.222	0.175	-0.085	-0.246	0.076	0.013	-0.202	0.227	-0.072	-0.235	0.091				
p,p'-DDT	0.042	-0.205	0.289	-0.063	-0.256	0.129	0.075	-0.158	0.308	-0.138	-0.327	0.050	-0.102	-0.353	0.149	-0.041	-0.233	0.150				
Dieldrin	-0.012	-0.310	0.287	-0.028	-0.261	0.204	-0.092	-0.373	0.188	0.064	-0.165	0.293	0.068	-0.235	0.371	-0.204	-0.432	0.024	†			
cis-HCE	0.136	-0.149	0.420	0.047	-0.175	0.270	0.050	-0.219	0.320	-0.003	-0.222	0.216	-0.087	-0.377	0.203	0.032	-0.189	0.254				
HCB	0.216	-0.174	0.606	-0.052	-0.357	0.253	0.026	-0.344	0.395	-0.077	-0.378	0.223	-0.052	-0.450	0.346	0.051	-0.252	0.354				
β-HCH	-0.032	-0.286	0.222	-0.050	-0.248	0.147	0.057	-0.182	0.296	-0.107	-0.301	0.087	-0.016	-0.274	0.242	-0.006	-0.203	0.190				
Mirex	0.218	-0.068	0.503	0.043	-0.182	0.267	-0.030	-0.302	0.241	0.073	-0.148	0.294	-0.166	-0.457	0.126	0.025	-0.198	0.248				
Parlar-26	0.031	-0.167	0.229	-0.006	-0.160	0.149	-0.012	-0.198	0.175	0.006	-0.146	0.158	0.022	-0.180	0.223	-0.029	-0.182	0.124				
Parlar-50	0.046	-0.177	0.270	-0.012	-0.186	0.162	-0.002	-0.213	0.209	-0.010	-0.182	0.162	0.021	-0.207	0.248	-0.015	-0.189	0.158				
	Androstenedione/DHEA			Testosterone/Androstenedione			Cortisol			Cortisone			Cortisone/Cortisol			Adrenal androgen/Glucocorticoid						
	β	95%CI		β	95%CI		β	95%CI		β	95%CI		β	95%CI		β	95%CI					
Oxychlordane	0.119	-0.217	0.455	0.018	-0.140	0.175	0.214	-0.265	0.692	0.374	-0.302	1.050	0.160	-0.145	0.465	-0.361	-1.139	0.416				
cis-Nonachlor	0.142	-0.169	0.453	0.029	-0.117	0.175	0.229	-0.215	0.672	0.463	-0.161	1.087	0.234	-0.046	0.515	-0.463	-1.181	0.255				
trans-Nonachlor	0.201	-0.103	0.505	0.027	-0.116	0.170	0.276	-0.157	0.709	0.517	-0.092	1.126	†	0.241	-0.033	0.516	†	-0.533	-1.234	0.168		
p,p'-DDD	0.091	-0.080	0.262	0.028	-0.052	0.108	0.208	-0.034	0.450	†	0.358	0.017	0.699	*	0.150	-0.004	0.304	†	-0.412	-0.803	-0.021	*
o,p'-DDE	-0.066	-0.266	0.134	0.027	-0.066	0.121	-0.176	-0.460	0.108	-0.030	-0.434	0.374	0.146	-0.034	0.327	0.088	-0.376	0.551				
p,p'-DDE	0.079	-0.179	0.337	0.112	-0.007	0.231	†	0.106	-0.261	0.474	0.285	-0.233	0.803	0.179	-0.054	0.411	-0.333	-0.928	0.261			
o,p'-DDT	-0.084	-0.333	0.164	0.048	-0.068	0.164	-0.269	-0.620	0.083	-0.058	-0.560	0.443	0.210	-0.013	0.433	†	0.143	-0.432	0.718			
p,p'-DDT	0.061	-0.231	0.353	0.116	-0.019	0.251	†	-0.045	-0.461	0.371	0.207	-0.380	0.795	0.253	-0.009	0.514	†	-0.167	-0.842	0.508		
Dieldrin	-0.272	-0.621	0.076	0.112	-0.051	0.275	-0.203	-0.704	0.297	-0.274	-0.982	0.434	-0.071	-0.391	0.249	0.256	-0.557	1.069				
cis-HCE	0.119	-0.217	0.455	0.018	-0.140	0.175	0.214	-0.265	0.692	0.374	-0.302	1.050	0.160	-0.145	0.465	-0.361	-1.139	0.416				
HCB	0.102	-0.359	0.564	-0.025	-0.241	0.191	0.317	-0.339	0.973	0.499	-0.428	1.425	0.182	-0.237	0.600	-0.420	-1.486	0.647				
β-HCH	0.010	-0.290	0.309	0.063	-0.077	0.202	0.004	-0.422	0.431	0.012	-0.592	0.615	0.007	-0.265	0.280	-0.014	-0.707	0.679				
Mirex	0.191	-0.148	0.529	-0.055	-0.214	0.103	0.229	-0.254	0.712	0.510	-0.170	1.189	0.280	-0.025	0.585	†	-0.525	-1.306	0.257			
Parlar-26	-0.051	-0.285	0.183	0.017	-0.092	0.127	0.044	-0.289	0.377	0.091	-0.380	0.562	0.047	-0.165	0.260	-0.040	-0.581	0.501				
Parlar-50	-0.036	-0.300	0.228	0.014	-0.110	0.137	0.028	-0.348	0.404	0.123	-0.408	0.655	0.095	-0.144	0.334	-0.050	-0.661	0.560				
	SHBG			Prolactin																		
	β	95%CI		β	95%CI																	
Oxychlordane	0.060	-0.118	0.238	0.092	-0.149	0.332																
cis-Nonachlor	0.057	-0.108	0.221	0.076	-0.147	0.298																
trans-Nonachlor	0.059	-0.102	0.220	0.085	-0.134	0.303																
p,p'-DDD	0.064	-0.026	0.155	0.120	0.000	0.241	†															
o,p'-DDE	-0.004	-0.109	0.102	-0.048	-0.191	0.094																
p,p'-DDE	0.074	-0.061	0.210	0.092	-0.091	0.275																
o,p'-DDT	-0.002	-0.133	0.130	-0.009	-0.186	0.169																
p,p'-DDT	0.034	-0.120	0.188	0.029	-0.178	0.237																
Dieldrin	0.014	-0.172	0.200	-0.199	-0.453	0.055																
cis-HCE	0.060	-0.118	0.238	0.092	-0.149	0.332																
HCB	0.116	-0.127	0.359	0.128	-0.202	0.458																
β-HCH	0.125	-0.031	0.282	0.009	-0.207	0.225																
Mirex	0.021	-0.159	0.200	0.120	-0.121	0.362																
Parlar-26	0.037	-0.086	0.160	-0.022	-0.188	0.145																
Parlar-50	0.030	-0.110	0.169	-0.002	-0.190	0.186																

Adjusted regression coefficients (β) and 95% confidence intervals (CIs) for the association between a 10-fold increase of OCP and log10-transformed hormone levels as determined by a linear regression model

Each OCP was introduced into the model separately and adjusted for maternal age, parity, and gestational age.

*P < 0.05, **P < 0.01, † P <0.1

Supplemental Table S1 Concentrations of organochlorine pesticides in maternal blood all measured of original cohort (n=379)

Persistent organochlorine pesticides	Detection limit (pg/g-wet)	>DL (%)	Minimum	Percentile			Maximum
				25th	50th	75th	
Aldrin	1.00	0.3				<DL	12.83
Chlordanes							
oxychlordane	0.90	100.0	7.93	27.05	39.67	56.02	250.94
<i>cis</i> -Chlordane	0.70	58.8		<DL	1.15	2.29	17.53
<i>trans</i> -Chlordane	0.50	45.4			<DL	0.71	3.79
<i>cis</i> -Nonachlor	0.40	100.0	1.63	6.76	9.97	14.36	38.07
<i>trans</i> -Nonachlor	0.50	100.0	13.14	49.70	71.52	107.59	513.52
DDTs							
<i>o,p'</i> -DDD	0.50	12.4				<DL	1.16
<i>p,p'</i> -DDD	0.40	89.7	<DL	0.94	1.48	2.29	9.04
<i>o,p'</i> -DDE	0.40	85.0	<DL	0.75	1.27	1.82	6.20
<i>p,p'</i> -DDE	0.60	100.0	99.52	401.53	650.99	1011.48	4575.67
<i>o,p'</i> -DDT	0.60	7.6	<DL	2.27	3.48	4.86	17.15
<i>p,p'</i> -DDT	0.40	100.0	2.38	16.63	23.16	33.99	121.52
Dieldrin	0.80	100.0	4.11	12.08	16.42	22.62	71.52
Endrin	1.00	0.0					<DL
Heptachlors							
Heptachlor	0.80	0.5				<DL	1.14
<i>trans</i> -HCE	1.00	0.0					<DL
<i>cis</i> -HCE	0.40	100.0	6.17	18.78	26.44	37.28	200.53
HCB	0.90	100.0	34.94	80.24	101.65	130.06	245.48
HCHs							
α-HCH	0.70	69.1		<DL	0.90	1.32	3.89
β-HCH	0.60	100.0	19.95	105.05	154.45	244.76	1667.12
γ-HCH	0.90	59.1		<DL	1.05	1.63	100.92
δ-HCH	0.70	0.8				<DL	1.11
Mirex	0.50	100.0	0.88	4.07	5.95	8.26	34.97
Toxaphenes							
Parlar-26	1.00	97.1	<DL	2.87	4.39	6.65	20.82
Parlar-41	0.70	26.9			<DL	0.72	1.96
Parlar-40	2.00	0.5				<DL	2.43
Parlar-44	2.00	1.6				<DL	2.84
Parlar-50	2.00	96.0	<DL	4.36	6.52	9.68	29.29
Parlar-62	6.00	0.0					<DL

DL, detection limit; DDD, dichlorodiphenyldichloroethane; DDE, dichlorodiphenyldichloroethylene; DDT, dichlorodiphenyltrichloroethane; HCB, hexachlorobenzene; HCE, heptachlor epoxide; HCH, hexachlorocyclohexane.

Supplemental table S2 Maternal and infant characteristics and concentrations of OCPs

characteristics		n	o,p'-DDT	p,p'-DDT	o,p'-DDE	p,p'-DDE	p,p'-DDD	cis-Nonachlor	trans-Nonachlor	oxychlordane
Mother			ρ	ρ	ρ	ρ	ρ	ρ	ρ	ρ
Age at delivery (years)			0.009	0.102	0.030	0.270**	0.137*	0.267**	0.311**	0.350**
Pre-pregnancy BMI (kg/m2)			0.062	0.118	0.119	0.003	0.052	0.089	-0.011	-0.093
			Med (min-max)	Med (min-max)	Med (min-max)	Med (min-max)	Med (min-max)	Med (min-max)	Med (min-max)	Med (min-max)
Educational level	≤12 years	100	3.01 (2.09, 4.47)	21.59 (15.41, 32.84)	1.16 80.70, 1.71)	565.05 (376.81, 942.71)	1.62 (0.88, 2.44)	9.88 (7.22, 14.64)	72.73 (52.69, 108.21)	39.83 (27.1, 56.02)
	>12 years	132	3.54 (2.42, 4.99)	25.32 (16.37, 34.77)	1.33 (0.96, 1.86)	634.71 (422.04, 976.14)	1.69 (1.03, 2.58)	10.78 (6.85, 15.13)	78.85 (51.80, 118.08)	40.22 (28.87, 57.78)
Annual Household income	<5 million yen per year	166	3.27 (2.22, 4.66)	22.35 (16.38, 33.65)	1.26 (0.71, 1.74)	619.26 (411.26, 942.60)	1.62 (0.99, .53)	9.93 (6.71, 14.35)	* 70.06 (50.04, 111.09)	* 39.07 (27.61, 56.02)
	≥5 million yen per year	66	3.64 (2.41, 5.06)	24.18 (15.54, 38.90)	1.23 (0.77, 2.05)	633.52 (392.24, 1302.85)	1.68 (0.98, 2.58)	11.91 (8.21, 15.98)	86.66 (62.34, 110.04)	45.83 (30.02, 66.07)
Smoking during pregnancy	No	190	3.46 (2.37, 4.66)	23.74 (16.38, 33.93)	1.26 (0.73, 1.77)	617.59 8409.71, 971.83)	1.61 (0.98, 2.57)	10.70 (7.17, 15.02)	76.63 (54.06, 112.12)	40.31 (29.25, 57.75)
	Yes	42	3.03 (1.79, 5.03)	21.09 (14.17, 34.22)	1.17 (0.70, 1.84)	625.95 (409.34, 944.10)	1.79 (1.07, 2.39)	8.94 (6.01, 15.10)	69.19 (48.19, 109.46)	38.64 (23.48, 51.97)
Alcohol consumption during pregnancy	No	154	3.10 (2.21, 4.67)	* 22.62 (15.54, 33.44)	1.22 (0.69, 1.72)	60.5.48 (412.66, 971.83)	1.62 (0.99, 2.55)	10.14 (6.90, 14.76)	74.14 (51.75, 112.12)	40.13 (28.81, 58.13)
	Yes	78	3.86 (2.56, 4.98)	24.14 (17.27, 33.98)	1.27 (0.90, 1.87)	648.50 (406.30, 976.56)	1.67 (0.87, 2.41)	11.04 (7.29, 15.25)	78.85 (52.92, 108.95)	40.04 (28.87, 56.02)
Parity	0	120	3.39 (2.38, 4.67)	24.38 (17.17, 33.92)	1.35 (0.81, 1.83)	652.69 (453.78, 1002.45)	1.64 (1.00, 2.52)	11.52 (7.50, 15.13)	* 87.74 (56.35, 117.19)	* 42.99 (32.00, 60.65)
	≥1	112	3.24 (2.22, 4.78)	21.98 (14.92, 34.69)	1.13 (0.69, 1.71)	564.40 (336.51, 938.47)	1.65 (0.91, 2.62)	9.5 (6.37, 14.06)	70.05 (45.60, 97.48)	38.97 (26.35, 54.44)
Blood sampling period	During pregnancy	159	3.42 (2.25, 4.72)	22.49 (15.57, 33.95)	1.22 (0.73, 1.83)	626.50 (412.96, 941.47)	1.51 (0.99, 2.28)	10.01 (7.06, 14.87)	70.38 (21.93, 105.61)	39.19 (27.65, 55.64)
	After delivery	73	3.36 (2.28, 4.48)	23.77 (19.33, 34.17)	1.35 (0.71, 1.73)	614.51 (339.28, 1008.37)	1.76 (0.87, 2.84)	11.15 (6.86, 16.79)	87.82 (51.95, 124.70)	44.66 (29.31, 60.98)
Type of delivery	Vaginal	230	3.36 (2.27, 4.68)	22.84 816.14, 33.93)	1.25 (0.72, 1.77)	619.26 8410.14, 964.80)	1.62 (0.98, 2.53)	10.33 (7.03, 15.04)	75.08 (51.89, 110.01)	39.87 (28.87, 57.31)
	Caesarian section	2	3.70 (3.03, 4.36)	36.58 (23.77, 49.38)	1.40 (0.91, 1.88)	688.72 (304.51, 1072.92)	2.87 (2.23, 3.5)	18.84 (12.12, 25.55)	119.01 (91.04, 146.97)	55.41 (40.2, 70.62)
Infant			ρ	ρ	ρ	ρ	ρ	ρ	ρ	ρ
Birth weight			0.022	-0.025	0.005	0.002	-0.087	-0.057	-0.057	-0.061
Gestational Age			0.066	0.037	0.039	0.117	-0.013	0.025	0.035	0.045
			Med (min-max)	Med (min-max)	Med (min-max)	Med (min-max)	Med (min-max)	Med (min-max)	Med (min-max)	Med (min-max)
Sex	Male	106	3.39 (2.42, 4.42)	23.90 (16.56, 33.88)	1.18 (0.72, 1.66)	641.93 (405.32, 934.78)	1.70 (1.04, 2.35)	10.29 (7.11, 15.11)	75.82 (53.44, 118.34)	40.22 (29.26, 57.54)
	Female	126	3.36 (2.20, 4.97)	21.96 (15.78, 34.45)	1.30 (0.72, 1.87)	611.15 (4101.00, 998.41)	1.60 (0.93, 2.66)	10.42 (6.80, 15.04)	74.66 851.75, 107.06)	39.87 (28.34, 57.15)

Supplemental table S1 Maternal and infant characteristics and concentrations of OCPs (continued)

Characteristics		n	Dieldrin	cis-HCE	HCB	β-HCH	Mirex	Parlar-26	Parlar-50
Mother			ρ	ρ	ρ	ρ	ρ	ρ	ρ
Age at delivery (years)			0.108	0.254**	0.119*	0.464**	0.513**	0.176**	0.181**
Pre-pregnancy BMI (kg/m2)			0.221**	0.177**	0.101	0.147*	-0.074	0.240**	0.240**
			Med (min-max)	Med (min-max)	Med (min-max)	Med (min-max)	Med (min-max)	Med (min-max)	Med (min-max)
Educational level	≤12 years	100	16.55 (12.52, 22.84)	26.07 (18.56, 40.28)	101.71 (80.26, 130.96)	154.79 (96.08, 262.30)	5.99 (4.08, 8.34)	4.85 (3.17, 7.55)	7.02 (4.61, 1028)
	>12 years	132	16.80 (12.11, 21.59)	26.91 (18.96, 37.13)	106.79 (85.26, 167.25)	154.31 (109.21, 220.69)	6.11 (4.31, 8.59)	4.05 (2.56, 6.68)	6.50 (3.88, 9.48)
Annual Household income	<5 million yen per year	166	15.93 (12.02, 20.99)	26.07 (18.44, 35.00)	102.17 (80.36, 129.52)	153.64 (100.87, 209.23)	5.76 (3.88, 7.79)	** 4.32 (2.69, 6.82)	6.48 (4.25, 9.48)
	≥5 million yen per year	66	17.89 (12.60, 24.41)	26.55 (19.17, 43.07)	111.51 (85.53, 145.40)	165.66 (113.97, 279.53)	7.44 (4.82, 11.64)	5.22 (3.14, 7.61)	7.69 (4.33, 11.64)
Smoking during pregnancy	No	190	16.86 (12.35, 22.47)	26.79 (19.14, 37.90)	103.82 (83.69, 131.84)	158.46 (103.79, 241.30)	6.16 (4.51, 8.61)	4.50 (2.84, 6.60)	6.82 (4.32, 9.74)
	Yes	42	15.51 (11.41, 21.31)	24.39 (16.80, 35.42)	104.48 (74.82, 132.31)	150.87 (103.84, 184.91)	5.69 (3.73, 7.82)	4.23 (2.73, 8.24)	5.88 (3.75, 11.43)
Alcohol consumption during pregnancy	No	154	16.80 (12.14, 22.82)	27.18 (18.91, 39.08)	105.46 (81.20, 133.02)	162.80 (104.40, 244.79)	6.04 (4.11, 8.38)	4.19 (2.82, 6.82)	6.40 (4.28, 9.58)
	Yes	78	16.35 (12.42, 21.66)	24.82 (18.42, 35.69)	99.34 (86.16, 130.72)	146.89 (102.56, 202.87)	6.09 (4.11, 8.61)	4.54 (2.91, 7.58)	7.32 (4.44, 10.56)
Parity	0	120	17.16 (12.52, 21.71)	26.79 (19.16, 36.85)	109.93 (91.03, 131.94)	** 165.19 (114.52, 271.53)	* 5.98 (4.14, 8.81)	5.23 (2.96, 7.20)	7.54 (4.54, 9.99)
	≥1	112	16.35 (12.05, 22.66)	25.17 (18.19, 40.63)	95.36 (72.71, 129.15)	143.66 (90.00, 211.57)	6.19 (4.11, 8.47)	4.02 (2.72, 6.68)	5.94 (3.85, 9.66)
Blood sampling period	During pregnancy	159	17.59 (12.39, 22.87)	26.44 (18.91, 38.12)	104.06 (85.45, 130.56)	154.13 (108.08, 218.60)	5.88 (4.07, 7.86)	4.50 (2.93, 7.08)	7.16 (4.25, 9.72)
	After delivery	73	15.51 (12.06, 21.32)	25.10 (18.50, 36.78)	103.73 (75.77, 138.73)	158.62 (94.33, 254.44)	6.76 (4.54, 10.19)	4.33 (2.56, 7.49)	6.42 (4.45, 10.72)
Type of delivery	Vaginal	230	16.61 (12.16, 22.44)	26.15 (18.76, 37.42)	103.99 (82.85, 131.26)	154.31 (104.40, 237.67)	6.04 (4.11, 8.51)	4.41 (2.84, 7.09)	6.55 (4.28, 9.79)
	Caesarian section	2	18.66 (16.82, 20.50)	36.20 (28.26, 44.14)	134.17 (85.55, 182.79)	154.45 (68.50, 240.39)	13.99 (4.84, 23.14)	7.67 (5.34, 10.00)	10.15 (7.63, 12.67)
Infant			ρ	ρ	ρ	ρ	ρ	ρ	ρ
Birth weight			-0.049	-0.101	-0.066	-0.128	-0.030	-0.024	-0.022
Gestational Age			-0.035	-0.082	0.052	0.061	0.027	0.024	-0.018
			Med (min-max)	Med (min-max)	Med (min-max)	Med (min-max)	Med (min-max)	Med (min-max)	Med (min-max)
Sex	Male	106	15.92 (12.07, 22.55)	26.39 (19.22, 40.80)	101.76 (85.53, 130.85)	153.65 (107.63, 237.67)	6.04 (4.53, 8.94)	4.50 (2.91, 6.86)	6.64 (4.33, 10.27)
	Female	126	17.07 (12.51, 21.96)	26.15 (18.49, 35.42)	104.60 (78.58, 133.01)	155.04 (102.56, 240.78)	6.04 (4.03, 8.41)	4.24 (2.73, 7.36)	6.50 (4.25, 9.74)

Supplemental Table S3 Distribution of steroids and reproductive hormones among all measured of original cohort (n=295)

	DL	n	>DL (%)	Total (n=295)			n	>DL (%)	Boys (n=106)			n	>DL (%)	Girls (n=126)			P-value
				25%	Med	75%			25%	Med	75%			25%	Med	75%	
Steroid hormones																	
Progesterone (ng/mL)	0.01	295	100	175.5	218.8	278.8	135	100	183.8	225.9	285.6	160	100	167.6	209.0	275.6	0.184
Testosterone (pg/mL)	0.01	295	100	59.8	83.9	114.1	135	100	76.5	98.9	126.3	160	100	52.1	70.1	96.8	<0.001
Estradiol (ng/mL)	0.01	295	99.7	3.29	4.70	7.10	135	99.3	3.33	4.86	7.42	160	100	3.16	4.68	6.61	0.227
DHEA (ng/mL)	0.01	295	100	1.77	2.19	2.99	135	100	1.59	2.08	2.76	160	100	1.91	2.34	3.22	
Androstenedione (ng/mL)	0.01	295	99.3	0.36	0.46	0.58	135	98.5	0.38	0.47	0.61	160	99.4	0.35	0.45	0.58	
Cortisol (ng/mL)	0.25	295	97.6	22.7	38.9	63.6	135	98.5	22.5	38.3	65.3	160	96.9	22.8	39.2	62.8	
Cortisone (ng/mL)	0.10	295	94.9	69.9	93.9	123.0	135	97.0	70.5	95.3	123.4	160	93.1	69.7	93.0	123.0	
Steroid Hormone Binding Globulin (nmol/L)	1.10	295	100	13.3	15.8	19.0	135	100	13.9	16.5	19.3	160	100	13.0	15.5	18.7	0.079
Lutheling Hormone (mIU/mL)	0.50	288	16.3			<DL	132	34.8		<DL	0.84	156	0.6			<DL	<0.001
Follicle Stimulating Hormone (mIU/mL)	0.50	287	20.9			<DL	132	45.5		<DL	0.66	155	0			<DL	<0.001
Inhibin B (pg/mL)	11	295	59.7	5.5	23.2	44.6	135	98.5	33.9	44.0	58.3	160	26.9		<DL	12.4	<0.001
Insulin-like factor 3 (ng/mL)	0.01	157	100	0.23	0.27	0.32	132	100	0.25	0.29	0.34	25	100	0.17	0.18	0.23	<0.001
Prolactin (ng/mL)	1.0	289	99.7	63.1	85.8	116.0	132	100	65.4	85.2	115.0	157	99.6	61.4	86.0	118.0	0.986

P values were calculated by Mann-Whitney U test;

DHEA, dehydroepiandrosterone; DL, detection limit

Supplemental Table S4 Associations between OCPs exposure and steroid and reproductive hormone levels and sex interaction

	Progesterone				Estradiol				Testosterone				Estradiol/Testosterone				DEHA				Androstenedione			
	β	95%CI	$p^a)$	$p^b)$	β	95%CI	$p^a)$	$p^b)$	β	95%CI	$p^a)$	$p^b)$	β	95%CI	$p^a)$	$p^b)$	β	95%CI	$p^a)$	$p^b)$	β	95%CI	$p^a)$	$p^b)$
Oxychlordan	0.024	-0.189	0.238		0.025	-0.178	0.229		-0.065	-0.249	0.118		0.091	-0.099	0.281		0.067	-0.119	0.253		0.019	-0.137	0.175	
cis-Nonachlor	0.022	-0.166	0.210	*	0.010	-0.170	0.190		-0.030	-0.192	0.132		0.040	-0.128	0.208		0.055	-0.108	0.218	*	0.039	-0.098	0.176	
trans-Nonachlor	0.014	-0.172	0.200	*	0.005	-0.173	0.184		-0.049	-0.209	0.112		0.054	-0.112	0.221		0.046	-0.116	0.208	*	0.038	-0.098	0.175	
p,p'-DDD	0.004	-0.111	0.119	†	-0.102	-0.211	0.008	†	-0.054	-0.153	0.045		-0.047	-0.150	0.055		-0.091	-0.191	0.009	†	-0.043	-0.126	0.041	
o,p'-DDE	-0.044	-0.169	0.082		-0.017	-0.136	0.102		-0.034	-0.142	0.074		0.017	-0.094	0.128		0.039	-0.070	0.149		-0.027	-0.118	0.064	
p,p'-DDE	0.017	-0.149	0.182		0.027	-0.130	0.183		-0.031	-0.172	0.110		0.058	-0.087	0.202	*	-0.029	-0.172	0.114		-0.060	-0.179	0.060	
o,p'-DDT	-0.069	-0.210	0.073		-0.035	-0.169	0.099		-0.024	-0.146	0.097		-0.011	-0.136	0.114		0.067	-0.056	0.190		-0.031	-0.134	0.071	
p,p'-DDT	-0.020	-0.198	0.158		-0.016	-0.186	0.154		0.007	-0.146	0.160		-0.023	-0.181	0.136		0.024	-0.130	0.179		-0.012	-0.141	0.118	
Dieldrin	-0.093	-0.304	0.118		0.022	-0.179	0.224		-0.059	-0.240	0.122		0.081	-0.106	0.269		0.164	-0.019	0.347	†	-0.022	-0.174	0.130	*
cis-HCE	-0.040	-0.238	0.158	†	-0.009	-0.198	0.181		-0.053	-0.224	0.118		0.044	-0.133	0.221		0.098	-0.074	0.271		-0.028	-0.173	0.117	
HCB	0.122	-0.178	0.422		0.033	-0.253	0.319		-0.060	-0.317	0.198		0.093	-0.173	0.359		0.126	-0.135	0.387		0.053	-0.165	0.271	
β -HCH	0.035	-0.151	0.220		0.050	-0.126	0.227		-0.014	-0.173	0.145		0.065	-0.099	0.229		0.056	-0.106	0.217		-0.004	-0.139	0.130	
Mirex	0.061	-0.146	0.268	†	0.027	-0.171	0.226		-0.154	-0.332	0.024	†	0.182	-0.003	0.366	†	0.018	-0.163	0.200		-0.019	-0.171	0.133	
Parlar-26	-0.046	-0.190	0.099		0.061	-0.077	0.198		-0.004	-0.128	0.121		0.065	-0.064	0.193		0.127	0.003	0.252	*	0.036	-0.069	0.140	
Parlar-50	-0.027	-0.181	0.127		0.032	-0.114	0.179		-0.010	-0.142	0.123		0.042	-0.095	0.179		0.127	-0.006	0.260	†	0.044	-0.067	0.156	
	Androstenedione/DHEA				Testosterone/Androstenedione				Cortisol				Cortisone				Cortisone/Cortisol				Adrenal androgen/ Glucocorticoid			
Oxychlordan	-0.051	-0.263	0.161		-0.083	-0.195	0.029		-0.084	-0.402	0.234		-0.014	-0.436	0.408	†	0.071	-0.138	0.281		0.100	-0.386	0.585	†
cis-Nonachlor	-0.018	-0.205	0.168		-0.067	-0.166	0.032	†	-0.009	-0.290	0.272		0.066	-0.306	0.438	*	0.076	-0.108	0.260	†	0.022	-0.405	0.450	*
trans-Nonachlor	-0.009	-0.194	0.175	*	-0.086	-0.184	0.011	†	-0.057	-0.334	0.220	*	0.040	-0.328	0.407	*	0.097	-0.085	0.280	†	0.044	-0.378	0.466	*
p,p'-DDD	0.050	-0.065	0.164		-0.013	-0.074	0.048		0.133	-0.038	0.305		0.186	-0.040	0.413		0.053	-0.059	0.165	†	-0.230	-0.490	0.031	†
o,p'-DDE	-0.066	-0.190	0.058		-0.008	-0.074	0.058		-0.139	-0.325	0.048		-0.088	-0.336	0.161		0.052	-0.071	0.174		0.142	-0.143	0.428	
p,p'-DDE	-0.032	-0.195	0.131		0.029	-0.057	0.115	†	-0.092	-0.337	0.153		0.017	-0.308	0.343		0.107	-0.054	0.269		0.006	-0.368	0.380	†
o,p'-DDT	-0.097	-0.237	0.042		0.006	-0.068	0.081		-0.215	-0.424	-0.006	*	-0.104	-0.384	0.176		0.110	-0.028	0.248		0.199	-0.123	0.520	
p,p'-DDT	-0.037	-0.213	0.140		0.019	-0.075	0.112	*	-0.064	-0.331	0.202		0.003	-0.350	0.356		0.067	-0.106	0.240	*	0.058	-0.348	0.465	
Dieldrin	-0.189	-0.397	0.019	†	-0.035	-0.145	0.075	*	-0.094	-0.409	0.221		-0.243	-0.661	0.176		-0.149	-0.356	0.057		0.312	-0.168	0.793	
cis-HCE	-0.189	-0.326	0.068		-0.024	-0.127	0.080	*	0.001	-0.297	0.298		-0.092	-0.486	0.302		-0.094	-0.289	0.101		0.139	-0.314	0.592	
HCB	-0.076	-0.373	0.221		-0.112	-0.269	0.046		0.014	-0.433	0.461		0.146	-0.448	0.740		0.132	-0.162	0.426		0.036	-0.647	0.719	
β -HCH	-0.063	-0.246	0.121		-0.009	-0.106	0.089		-0.070	-0.347	0.206		-0.035	-0.402	0.333		0.035	-0.147	0.217		0.101	-0.321	0.524	
Mirex	-0.037	-0.243	0.169		-0.134	-0.243	-0.026	*	-0.207	-0.515	0.100	*	-0.047	-0.456	0.362	*	0.161	-0.042	0.364		0.122	-0.349	0.593	*
Parlar-26	-0.092	-0.235	0.051		-0.039	-0.115	0.037		-0.070	-0.286	0.145		-0.100	-0.386	0.186		-0.031	-0.172	0.111		0.209	-0.119	0.536	
Parlar-50	-0.084	-0.237	0.068		-0.053	-0.134	0.028		-0.070	-0.300	0.159		-0.058	-0.362	0.247		0.012	-0.139	0.163		0.186	-0.163	0.536	
	SHBG				Prolactin																			
Oxychlordan	-0.014	-0.136	0.108		0.011	-0.144	0.167																	
cis-Nonachlor	0.004	-0.104	0.112		-0.041	-0.177	0.096																	
trans-Nonachlor	0.012	-0.095	0.119		0.003	-0.133	0.139																	
p,p'-DDD	0.058	-0.008	0.123		0.070	-0.013	0.153	†																
o,p'-DDE	-0.016	-0.087	0.056		-0.082	-0.172	0.009	†																
p,p'-DDE	0.001	-0.092	0.095		-0.060	-0.178	0.058	*																
o,p'-DDT	-0.006	-0.087	0.075		-0.090	-0.191	0.011	†																
p,p'-DDT	0.007	-0.095	0.109		-0.063	-0.191	0.065																	
Dieldrin	-0.020	-0.140	0.101		-0.201	-0.354	-0.048	*																
cis-HCE	0.040	-0.074	0.153		-0.070	-0.215	0.075																	
HCB	-0.029	-0.200	0.141		-0.057	-0.273	0.159																	
β -HCH	-0.002	-0.107	0.103		-0.078	-0.212	0.056																	
Mirex	-0.041	-0.160	0.078		-0.029	-0.180	0.121																	
Parlar-26	0.008	-0.075	0.090		-0.066	-0.171	0.040																	
Parlar-50	-0.011	-0.099	0.077		-0.069	-0.181	0.043																	

β s were changes of hormone levels (log 10 transformed) of 10 fold increase of each OCP, calculated by linear regression model.

^{a)} P for OCP adjusted for Maternal age, Parity, Gestational age, and (sex) x (each OCP); ^{b)} P for interaction of sex and OCP.

*P < 0.05, **P < 0.01, †P < 0.1